

		Luitpold Pharmaceuticals, Inc. US Physician Payments January 1, 2016 through December 31, 2016	Report			
Payee	Study Name 1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo-	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
	Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome -					
21ST CENTURY ONCOLOGY LLC	RLS-	FERREIRA	MICHELLE	MEDLEY	FL	\$ 12,722.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous					
A TERRELONGE MD PA	Injectafer - Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -I	TERRELONGE	ANTONIO	MIAMI	FL	\$ 264.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled					
	Study to Investigate the Treatment Response of Intravenous Injectafer Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin					
AFFILIATED PODIARTRISTS PA AHI ATLANTA, LLC	Levels in Patients with Iron deficient Anemia -I 1VIT13035	NOAR WOLF	Mark DOUGLAS	TOWSON ATLANTA	MD GA	\$ 378.00 \$ 29,430.00
	1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV					
ALL CARE CHIROPRACTIC & WELLNESS CENTER	iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer- vs. Int	Nair	Santosh	ORANGE CITY	FL	\$ 898.20
ANDERSON CLINICAL	1VIT14037 1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate	Anderson	Donald	Redlands	CA	\$ 8,918.00
	the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV iron and Compare the Safety, Effect on Quality of Life and Resource					
ANGELIQUE BARRETO M.D., P.C.	Utilization, of Injectafer- vs. Int 1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate	BARRETO	ANGELIQUE	OKLAHOMA CITY	ОК	\$ 567.00
	the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV iron and Compare the Safety, Effect on Quality of Life and Resource					
ANTIETAM ONCOLOGY&HEMATOLOGY GROUP,PC	Utilization, of Injectafer- vs. Int 1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled	HAMDAN	HIND	HAGERSTOWN	MD	\$ 45.00
	Study to Investigate the Efficacy and Safety of Injectaferferric carboxymaltose injection- in Patients with Cancer- and					
ANTIETAM ONCOLOGY&HEMATOLOGY GROUP,PC	Chemotherapy-related Anemia 1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate	HAMDAN	HIND	HAGERSTOWN	MD	\$ 14,080.00
	the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV iron and Compare the Safety, Effect on Quality of Life and Resource					
ARCHBOLD MEDICAL GROUP	Utilization, of Injectafer- vs. Int 1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate	COLEMAN	TERESA	THOMASVILLE	GA	\$ 210.00
	the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer-vs. Int	CORTEZ	ANDREW	PHOENIX		\$ 378.00
ARIZONA CENTER FOR NEUROSURGERY LTD.	1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate	CORTEZ	ANUREW	PHOENIX	NZ	\$ 378.00
ARIZONA CENTER FOR NEUROSURGERY LTD.	the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV iron and Compare the Safety, Effect on Quality of Life and Resource Utilization of Injections in the Injection of Injection of Injection in	MUSTAFA	ESMAT	PHOENIX	A7	\$ 45.00
THE STATE OF THE S	Utilization, of Injectafer- vs. Int 1VIT13035- A Multi-center, Randomized, Open-label, Controlled					+ 43.00
	Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin					
ARIZONA GASTROENTEROLOGY LTD ASA CLINICAL RESEARCH	Levels in Patients with Iron deficient Anemia -I 1/IT13032	CONTRERAS RABIEI	BRYAN ABBAS	TUCSON JUPITER	AZ FI	\$ 2,100.00 \$ 1,550.00
run dennem materiali	1VIT13035- A Multi-center, Randomized, Open-label, Controlled	TO SAME.	- Control of the Cont	2011121		2 1,330.00
	Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin					
ASC DEVELOPMENT COMPANY, LLC	Levels in Patients with Iron deficient Anemia -I 1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled	HARDI	ROBERT	CHEVY CHASE	MD	\$ 420.00
	Study to Investigate the Efficacy and Safety of Injectafer ferric carboxymaltose injection in Patients with Cancer - and					
ASHLAND BELLEFONTE OB-GYN ASSOCIATION IN ONCOLOGY & HEMATOLOGY	Chemotherapy-related Anemia 1VIT13032	JAIN GANDHI	KIRTI JITENDRA	ASHLAND KNOXVILLE	KY TN	\$ 567.00 \$ 2.157.20
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled					
	Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin					
BELMONT MEDICAL GROUP BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC	Levels in Patients with Iron deficient Anemia -I 1VIT14039	PRUITT Chaitowitz	RONALD Mark	NASHVILLE NEW YORK	TN NY	\$ 5,200.00 \$ 12,014.00
	1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV					
BOND & STEELE CLINIC, P.A.	Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer- vs. Int	HLALAH	OSAMA	WINTER HAVEN	FL	\$ 567.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled					
	Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin				_	
BOND CLINIC PA	Levels in Patients with Iron deficient Anemia -I	HLALAH	OSAMA	WINTER HAVEN	FL	\$ 567.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous					
BRISTOL HOSPITAL INC	Injectafer - Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -I	ZAKKO	SALAM	BRISTOL	ст	\$ 4,673.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous					
BROOKWOOD INTERNAL MEDICINE, P.C.	Injectafer - Ferric Carboxymaltose - vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -I	WILLIAMS	HAYES	VESTAVIA	A1	\$ 1,400.00
BROOKWOOD INTERNAL WILDICINE, F.C.	1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer-	WILLDAWIS	TIALES	VESTAVIA	AL	3 1,400.00
BROWARD MEDICAL PHYSICIAN ASSOCIATES INC	Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	Rielo	Diego	PEMBROKE PINES	FI	\$ 7,685.80
CANCER CARE CENTER	1VIT13032 1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate	ROSS	DAVID	ROCKLEDGE	FL	\$ 1,030.00
	the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV iron and Compare the Safety, Effect on Quality of Life and Resource					
CANCER CARE CENTERS OF BREVARD	Utilization, of Injectafer- vs. Int 1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo-	ROSS	DAVID	ROCKLEDGE	FL	\$ 150.00
	Controlled Study to Investigate the Efficacy and Safety of Injectafer Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome					
CARDIOVASCULAR SPECIALISTS OF THE CUMBERLANDS P		ADAMS	Mark	LONDON	КУ	\$ 7,000.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous					
CEDARS SINAI MEDICAL CENTER	Injectafer Ferric Carboxymaltose - vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I	MELMED	GIL	LOS ANGELES	CA	\$ 2,188.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled					
	Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin					
CENTER FOR ADVANCED GASTROENTEROLOGY LLC	Levels in Patients with Iron deficient Anemia -I 1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo-	HILAL	RAOUF	MAITLAND	PL	\$ 4,200.00
CENTED FOR RDAIN AND NEUROCARE U.C.	Controlled Study to Investigate the Efficacy and Safety of Injectafer - Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - ps c	CHNAWADDAME	DIRAMANI	ELLICOTT CITY	MD	6 015050
CENTER FOR BRAIN AND NEUROCARE LLC CENTER FOR CANCER & BLOOD	RLS- 1VIT13032 1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate	GUNAWARDANE BOCCIA	RUWANI RALPH	BETHESDA	MD MD	\$ 9,150.00 \$ 4,760.00
	1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV iron and Compare the Safety, Effect on Quality of Life and Resource					
CENTER FOR CANCER AND BLOOD DISORDERS	Utilization, of Injectafer-vs. Int 1/1/114039- A Multi-center, Randomized, Double-blinded, Controlled	BOCCIA	RALPH	BETHESDA	MD	\$ 7,000.00
	Study to Investigate the Efficacy and Safety of Injectafer -ferric carboxymaltose injection- in Patients with Cancer- and					
CENTER FOR CANCER AND BLOOD DISORDERS CENTRAL KENTUCKY RESEARCH ASSOCIATION INC.	Chemotherapy-related Anemia 1/1714037	BOCCIA ADAMS	RALPH Mark	BETHESDA LONDON	MD KY	\$ 6,710.00 \$ 4,100.00
The state of the s	1VIT14038- A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer Ferric					.,200.00
CHAD BOOMERSHINE	Carboxymaltose- in the Treatment of Iron Deficient patients with Fibromyalgia.					\$ 850.50
CHARLOTTE GASTROENTEROLOGY & HEPATOLOGY, PLLC	1VIT13035	WILSON	JASON	CHARLOTTE	NC	\$ 4,650.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous					
CHARLOTTE GASTROENTEROLOGY & HEPATOLOGY, PLLC	Injectafer - Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -I	WILSON	JASON	HUNTERSVILLE	NC	\$ 7,800.00
	1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV					
CHI ST VINCENT HOSPITAL HOT SPRINGS	iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer- vs. Int	CLEVELAND	LYNN	HOT SPRINGS	AR	\$ 435.00
CINCINNATI CHILDREN'S HOSPITAL	Venofer Pediatric Registry	VANDEVOORDE	RENE	NASHVILLE	TN	\$ 6,400.00

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of DI / Load Receasehor	Total	
CLEVELAND CLINIC FOUNDATION CLINICAL RESEARCH SOLUTIONS	Venofer Pediatric Registry 1VIT14038	DELL BOOMERSHINE	KATHERINE CHAD	CLEVELAND NASHVILLE	OH TN	\$	400.00 5 952 50
CLINICAL RESEARCH SOLUTIONS		BOOMERSHINE	CHAD	NASHVILLE	IN	\$	5,952.50
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous						
Clinical Research Solutuions, LLC	InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -I	FRIEDENBERG	KEITH	MENTOR	ОН	5	10.770.00
	1VIT14038- A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of InjectaferFerric						
	Carboxymaltose- in the Treatment of Iron Deficient patients with						
Clinical Research Solutuions, LLC	Fibromyalgia. 1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate	BOOMERSHINE	CHAD	NASHVILLE	TN	\$ 1	36,696.25
	the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV iron and Compare the Safety, Effect on Quality of Life and Resource						
COASTAL CAROLINA HEALTH CARE PA	Utilization, of Injectafer- vs. Int	MONTERO	MANUEL	NEW BERN	NC	\$	378.00
Coastal Clinical Research Inc. Coastal Clinical Research Inc.	1VIT14037 1VIT14039	LEDET LEDET	MICHAEL MICHAEL	MOBILE MOBILE	AL	\$	19,574.50 13,480.95
COMPASSIONATE CANCER CARE MEDICAL GROUP, INC. COMPASSIONATE CANCER CARE MEDICAL GROUP, INC.	1VIT14039 1VIT14039	CHOI JHANGIANI	BRIAN HARESH	RIVERSIDE FOUNTAIN VALLEY	CA CA	\$	11,120.00 16,625.00
	1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer-						
CONSULTANTS IN NEUROLOGY. PA	Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	ROWE	VERNON	LENEXA	KS		7.567.00
CONSULTANTS IN NEUROLOGY, PA	1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate	ROWE	VERNON	LENEXA	KS	\$	7,567.00
	the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV iron and Compare the Safety, Effect on Quality of Life and Resource						
DANA FARBER CANCER INSTITUTE	Utilization, of Injectafer- vs. Int	OKAM	MAUREEN	BROOKLINE	MA	\$	1,575.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled						
	Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin						
DARTMOUTH-HITCHCOCK CLINIC SSP SPECIALTY SERVICE DAVID KUDROW	S Levels in Patients with Iron deficient Anemia -I 1VIT14037	SIEGEL	COREY	LEBANON	NH	\$	1,400.00 14,000.00
DATE RODIOW	1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate					7	14,000.00
	the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV iron and Compare the Safety, Effect on Quality of Life and Resource						
DELTA ONCOLOGY ASSOCIATES PC	Utilization, of Injectafer- vs. Int 1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo-	SHABAZZ	LLOYD	PORTSMOUTH	VA	\$	420.00
	Controlled Study to Investigate the Efficacy and Safety of Injectafer-						
DESERT NEUROLOGY ASSOCIATES, LLC	Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	THEUVENET	NICOLE	HENDERSON	NV	\$	9,717.00
1	1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer-						
DESERT VALLEY MEDICAL GROUP, INC.	Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RI S-	Anderson	Dennis	SAN BERNARDINO	CA	¢	7,000.00
INC.	1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo-			- AN DESIGNATION		~	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	Controlled Study to Investigate the Efficacy and Safety of Injectafer Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome						
DESERT VALLEY MEDICAL GROUP, INC. Desert Valley Research	RLS- 1VIT14037	Anderson Anderson	Donald Dennis	Redlands SAN BERNARDINO	CA CA	\$	630.00 17,348.00
DHARAM KUMBHANI	1VIT14037					\$	3,300.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled						
	Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin						
DIGESTIVECARE, INC.	Levels in Patients with Iron deficient Anemia -I 1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate	STONE	LISA	BEAVERCREEK	ОН	\$	45.00
	the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV						
DREXEL UNIVERSITY	iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer- vs. Int	STYLER	MICHAEL	PHILADELPHIA	PA	\$	1,470.00
EAST CAROLINA UNIVERSITY EDGARDO SANTIAGO-GUZMAN	Venofer Pediatric Registry 1VIT14039	HIDALGO	GUILLERMO	CHARLOTTE	NC	\$	400.00 7,080.00
EDGEMONT MEDICAL CLINIC	Venofer Pediatric Registry 1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo-	ZARITSKY	JOSHUA	WILMINGTON	DE	\$	7,400.00
	Controlled Study to Investigate the Efficacy and Safety of Injectafer						
EGRET BAY NEUROLOGY, PA	Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	FUJII	MAVIS	HOUSTON	TX	\$	16,717.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled						
	Study to Investigate the Treatment Response of Intravenous						
EHCA JOHNS CREEK, LLC	InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -I	SALZBERG	BRUCE	SUWANEE	GA	\$	378.00
Elite Research Institute	1VIT14037 1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled	Rielo	Diego	PEMBROKE PINES	FL	\$	4,500.00
	Study to Investigate the Efficacy and Safety of Injectaferferric carboxymaltose injection- in Patients with Cancer- and						
ELOY ROMAN MD PA	Chemotherapy-related Anemia	ROMAN	ELOY	MIAMI	FL	\$	19,955.00
	1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectaferferric						
ELOY ROMAN MD PA	carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	YANEZ	GIRALT	PEMBROKE PINES	FI	5	7,898.20
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled						.,
	Study to Investigate the Treatment Response of Intravenous						
EMORY DIALYSIS. LLC	InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -I	WOLF	DOUGLAS	ATLANTA	GA	Ś	4,500.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled						
	Study to Investigate the Treatment Response of Intravenous						
ENDOSCOPIC MICROSURGERY ASSOCIATES	Injectafer Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I	NOAR	Mark	TOWSON	MD	\$	232.00
ERIKA DRIVER-DUNCKLEY ETMC CANCER INSTITUTE CLINIC TRIALS	1VIT14037 1VIT14039	DRODER	ROBERT	TYLER	TX	\$ \$	7,000.00
ETMC CANCER INSTITUTE CLINIC TRIALS	1VIT14039	GROSS	GARY	TYLER	TX	\$	4,000.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled						
	Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin						
EVECON INC Feinstein Institute	Levels in Patients with Iron deficient Anemia -I 1VIT13032	WEBER SWAMINATH	JOHN ARUN	TROY NEW YORK	MI	\$	6,266.00 815.20
	1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled					~	313.20
	Study to Investigate the Efficacy and Safety of Injectaferferric carboxymaltose injection- in Patients with Cancer- and						
FLORIDA HEALTH SCIENCES CENTER INC	Chemotherapy-related Anemia 1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo-	JAGLAL	MICHAEL	TAMPA	FL	\$	567.00
	Controlled Study to Investigate the Efficacy and Safety of Injectafer						
FORT COLLINS NEUROLOGY PC	Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	CURIEL	MICHAEL	FORT COLLINS	со	\$	9,717.00
GARY GROSS	1VIT14039			+		\$	7,080.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous						
C ASTROCAUTEROLOGY ASSOCIATION	InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin	HOMONY	DOUGLAS	KINCEPORT	TN:	_	2 200 0
GASTROENTEROLOGY ASSOCIATES	Levels in Patients with Iron deficient Anemia -I	HOMOKY	DOUGLAS	KINGSPORT	IN	>	2,200.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous						
GASTROENTEROLOGY ASSOCIATES OF DOTHAN, PC	Injectafer - Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -I	RUTLAND	TRAVIS	DOTHAN	Al	¢	2,800.00
CASTROLINIEROLOGI ASSOCIATES OF DUTRAN, PC		NO IDAGO	1000	DO /TIMIN		,	4,auU.UU
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled						
	Study to Investigate the Treatment Response of Intravenous					5	2,100.00
GASTROENTEROLOGY CLINIC OF ACADIANIA	Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia J	ARTERRIEN	IAMES			۶	4,100.00
GASTROENTEROLOGY CLINIC OF ACADIANA	Injectafer - Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I	ARTERBURN	JAMES	LAFAYETTE	LA		
GASTROENTEROLOGY CLINIC OF ACADIANA	InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin	ARTERBURN	JAMES	LAFAYETTE	LA		
	Injectafer - Ferric Carboxymaltose vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - 1 1VIT1305- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin				TX	5	36 080 00
GASTROENTEROLOGY CLINIC OF ACADIANA GASTROENTEROLOGY CLINIC OF SAN ANTONIO, P.A.	InjectaferFerric Carboxymaltose- vs. Oral fron to Baseline Hepcidin Levels in Patients with fron deficient Anemia -1 1VT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous injectaferFerric Carboxymaltose- V. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1	ARTERBURN BULLOCK	JAMES JEFF	SAN ANTONIO	TX	\$	36,080.00
	InjectafeFerric Carboxymathose- vs. Oral fron to Baseline Hepcidin Levels in Patients with fron deficient Anemia -1 1VT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous injectaferFerric Carboxymathose- V. Oral fron to Baseline Hepcidin Levels in Patients with fron deficient Anemia -1 1VT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Teratement Response of Intravenous				TX	\$	36,080.00
	InjectafeFerric Carboxymaltose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Freatment Response of Infravenous InjectafeFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled				TX TX		36,080.00 15,978.00
GASTROENTEROLOGY CLINIC OF SAN ANTONIO, P.A.	InjectafeFerric Carbosymathose-vs. Oral fron to Baseline Hepcidin Levels in Patients with fron deficient Annemia -1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Trestment Response of Intravenous InjectaferFerric Carbosymathose-vs. Oral fron to Baseline Hepcidin Levels in Patients with fron deficient Anemia -1 IVIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Trestment Response of Intravenous InjectaferFerric Carbosymathose-vs. Oral fron to Baseline Hepcidin Levels in Patients with fron deficient Anemia -1	BULLOCK	JEFF	SAN ANTONIO	TX		
GASTROENTEROLOGY CLINIC OF SAN ANTONIO, P.A.	InjectafeFerric Carbosymathose- vs. Oral fron to Baseline Hepcidin Levels in Patients with fron deficient Annema -1 1VTT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Trestment Response of Intravenous injectaferFerric Carbosymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with fron deficient Anemia -1 1VTT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous injectaferFerric Carbosymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VTT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Teatment Response of Intravenous injectaferFerric Carbosymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VTT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Teratement Response of Intravenous	BULLOCK	JEFF	SAN ANTONIO	TX TX		
GASTROENTEROLOGY CLINIC OF SAN ANTONIO, P.A.	InjectafeFerric Carboxymaltose- vs. Oral fron to Baseline Hepcidin Levels in Patients with fron deficient Anemia -1 1VT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous injectaferFerric Carboxymaltose- vs. Oral fron to Baseline Hepcidin Levels in Patients with fron deficient Anemia -1 1VT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous InjectafeFerric Carboxymaltose- vs. Oral fron to Baseline Hepcidin Levels in Patients with fron deficient Anemia -1 1VT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous InjectafeFerric Carboxymaltose- vs. Oral fron to Baseline Hepcidin Levels in Patients with fron deficient Anemia -1	BULLOCK	JEFF	SAN ANTONIO	TX TX		

Multi-center, Randomized, Open-label, Controlled igate the Treatment Response of Intravenous ric Carbownalises v. Coral fron to Baseline Hepcidin this with Iron deficient Anemia 4. Multi-center, Randomized, Open-label, Controlled igate the Treatment Response of Intravenous ric Carbownalises v. Coral fron to Baseline Hepcidin this with Iron deficient Anemia 1. Bit Center, Randomized, Open-label froit to Evaluate ruran Hepcidin Levels to Predict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource injectafer vs. Int. Multi-center, Randomized, Open-label, Controlled igate the Treatment Response of Intravenous ric Carbownalises vs. Oral ron to Baseline Hepcidin sets with Iron deficient Anemia 4. Multi-center, Randomized, Open-label, Controlled igate the Treatment Response of Intravenous ric Carbownalises vs. Oral ron to Baseline Hepcidin sets with Iron deficient Anemia 4. Multi-center, Randomized, Oponibe-binded, Controlled igate the Efficacy and Safety of Injectafer - Jerric Presidest Anemia 4.	RINESMITH CHOKSHI WEBER WINKELMAN	Principal Investigator / Lead Researcher First Name SCOTT LAWRENCE	City of PI / Lead Researcher LUMA BOSSIER CITY	State of PI / Lead Researcher	Total \$	1,500.00
igate the Treatment Response of Intravenous Tre Carbowymalose-w, Orall ron to Baseline Hepcldin ints with Iron deficient Anemia . Multi-center, Randomized, Open-label, Controlled igate the Treatment Response of Intravenous ric Carbowymalose-w, Oral Iron to Baseline Hepcldin iss with Iron deficient Anemia -1 ill-Center, Randomized, Open Label Trai to Evaluate trum Hepcldin Levels to Predict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource injectatier-w, Intra- ligate the Treatment Response of Intravenous International Controlled igate the Treatment Response of Intravenous in Carbowymalose-w, Oral Iron to Saseline Hepcldin iss with Iron deficient Anemia -1 Multi-center, Randomized, Open-label, Controlled igate the Efficacy and Safety of Injectafer-ferric elipiection- in Pastents with Cancer- and related Anemia	iohnson Chokshi Weber			ОН	\$	1,500.00
ric Carboxymaltose - vs. Oral Iron to Baseline Hepcidin tis with Iron deficient Anemia - 1 was with Iron deficient Anemia - 1 was a series of the Carboxymaltose - vs. Oral Iron to Baseline Hepcidin tis with Iron deficient Anemia - 1 series - 1 was a series - vs. Oral Iron to Baseline Hepcidin tis with Iron deficient Anemia - 1 was a series - 1	iohnson Chokshi Weber			ОН	\$	1,500.00
Its with Iron deficient Anemia -1 Multi-center, Randomized, Open-label, Controlled igate the Treatment Response of Intravenous ric Carboxymaltose-vs. Oral Iron to Baseline Hepclidin sts with Iron deficient Anemia -1 diff-Center, Randomized, Open Label Trial to Evaluate rum Hepclidin Levels to Predict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource inectafer-vs. Intractafer-vs. Oral Iron to Saseline Hepcldin sts with Iron deficient Anemia -1 Multi-center, Randomized, Open-label, Controlled igate the Efficacy and Safety of Injectafer-derric einjection- in Pasients with Cancer- and related Anemia	iohnson Chokshi Weber			он	\$	1,500.00
igate the Treatment Response of Intravenous ric Carboymalbose vs. Carl Iron to Saseline Hepcidin int Centre, Randomized, Open Label Trial to Evaluate rum Hepcidin Levels to Predict Response to Oral or IV are the Safey, Effect on Quality of Life and Resource niectafer- vs. Int Wulti- center, Randomized, Open-label, Controlled igate the Treatment Response of Intravenous ric Carboymaltose- vs. Oral Iron to Baseline Hepcidin this with Iron deficient Anemia -1 Multi-center, Randomized, Double-blinded, Controlled igate the Efficacy and Safety of Injectaferferric elipication- In Baselins with Cancer- and related Anemia	CHOKSHI	LAWRENCE	BOSSIER CITY		ļ	
igate the Treatment Response of Intravenous ric Carboymalbose vs. Carl Iron to Saseline Hepcidin int Centre, Randomized, Open Label Trial to Evaluate rum Hepcidin Levels to Predict Response to Oral or IV are the Safey, Effect on Quality of Life and Resource niectafer- vs. Int Wulti- center, Randomized, Open-label, Controlled igate the Treatment Response of Intravenous ric Carboymaltose- vs. Oral Iron to Baseline Hepcidin this with Iron deficient Anemia -1 Multi-center, Randomized, Double-blinded, Controlled igate the Efficacy and Safety of Injectaferferric elipication- In Baselins with Cancer- and related Anemia	CHOKSHI	LAWRENCE	BOSSIER CITY			
Its with Iron deficient Anemia - Il Itili Center, Randomized, Open Label Trial to Evaluate erum Hepcidin Levels to Predict Response to Oral or IV are the Safey, Effect on Quality of Life and Resource njectafer-vs. Int Multi-center, Randomized, Open-label, Controlled igate the Treatment Response of Intravenous ric Carboxymaltose-vs. Oral Iron to Baseline Hepcidin ts with Iron deficient Anemia - I Multi-center, Randomized, Double-blinded, Controlled igate the Efficacy and Safety of Injectafer-ferric ei piejction- in Patients with Cancer- and orelated Anemia	CHOKSHI	LAWRENCE	BOSSIER CITY		l l	
Hil-Center, Randomized, Open Label Trial to Evaluate runn Hepdicin Levels to rredict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource niectafer-vs. In Multi-center, Randomized, Open-label, Controlled igaze the Treatment Response of Intravenous Tre Carbowynatiose-v. Oral Iron to Salenine Hepcidin tss with Iron deficient Anemia 1 Multi-center, Randomized, Double-binded, Controlled igaze the Efficacy and Safety of Injectafer-derric elipication- In Beatens with Cancer- and crelated Anemia	CHOKSHI	OWNERCE	BO33IER CITT	14	e	6,772.00
are the Safety, Effect on Quality of Life and Resource niectafer-vs. In Multi-center, Randomized, Open-label, Controlled rigate the Treatment Response of Intravenous for Carbowynalises vs. Oral Iron to Baseline Hepcidin tis with Iron deficient Anenias 1. Whitti-center, Randomized, Double-binded, Controlled gipts the Efficacy and Safety of Injectuferterric el piction- In Patients with Cancer- and crelated Anenia	WEBER			<u></u>	<u>, </u>	0,772.00
nijectafer- vs. Int Multi-center, Randomized, Open-label, Controlled igigate the Treatment Response of Intravenous ric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin nts with Iron deficient Anemia -1 Multi-center, Randomized, Double-blinded, Controlled igigate the Efficacy and Safety of Injectafer - Jerric ei injection- in Raients with Cancer- and related Anemia	WEBER				l l	
igate the Treatment Response of Intravenous ric Carbowymalose- vs. Oral I ron to Baseline Hepcidin ints with Iron deficient Anemia - I Multi-center, Randomized, Double-blinded, Controlled igate the Efficacy and Safety of Injectafer - Ferric el injection- In Patients with Cancer- and related Anemia		MANISH	CINCINNATI	ОН	\$	50.00
igate the Treatment Response of Intravenous ric Carbowymalose- vs. Oral I ron to Baseline Hepcidin ints with Iron deficient Anemia - I Multi-center, Randomized, Double-blinded, Controlled igate the Efficacy and Safety of Injectafer - Ferric el injection- In Patients with Cancer- and related Anemia						
nts with iron deficient Anemia - I Multi-center, Randomized, Double-blinded, Controlled igate the Efficacy and Safety of Injectafer-ferric e injection- in Patients with Cancer- and related Anemia					l l	
Multi-center, Randomized, Double-blinded, Controlled igate the Efficacy and Safety of Injectaferferric e injection- in Patients with Cancer- and related Anemia					L	
ilgate the Efficacy and Safety of Injectaferferric e Injection- in Patients with Cancer- and -related Anemia		JOHN JOHN	TROY BOSTON	MI MA	\$ 1	378.00 83,879.00
e injection- in Patients with Cancer- and r-related Anemia						
r-related Anemia					ı	
	DOWNIE KHAIR	BENJAMIN TINA	GEORGETOWN	TX	\$	7,080.00
	KHAIK	IINA	GETTYSBURG	PA	\$.	26,471.11
erum Hepcidin Levels to Predict Response to Oral or IV					l l	
are the Safety, Effect on Quality of Life and Resource njectafer- vs. Int	BUI	LYNNE	GILROY	CA	\$	4,650.00
	GUTER	KARL	GREAT FALLS	MT	\$	5,743.00
erum Hepcidin Levels to Predict Response to Oral or IV					ı	
are the Safety, Effect on Quality of Life and Resource					L	465.00
Double-Blind, Multi-Center, Randomized, Placebo-	SOTER	MARL	GREAT FALLS	IVII	-	405.00
dy to Investigate the Efficacy and Safety of Injectafer					l l	
naitose- in the Treatment of Restless Legs Syndrome -	DOHMEIER	CARMEN	GREENSBORO	NC	\$	9,717.00
					\$	14,160.00
Multi-center, Randomized, Double-blinded, Controlled ligate the Efficacy and Safety of Injectaferferric					l l	
e injection- in Patients with Cancer- and	DIAIAD	OSAMA	MUNITED HAY (FA)		١	7 000 ~-
llti-Center, Randomized, Open Label Trial to Evaluate	HEADNI	OSMINA	WINTER PAVEN	rs.	-	7,000.00
erum Hepcidin Levels to Predict Response to Oral or IV					ı	
njectafer- vs. Int	HAUT	MITCHELL	CANTON	ОН	L\$	1,800.00
llti-Center, Randomized, Open Label Trial to Evaluate					Ė	
njectafer- vs. Int	CASTINE	MICHAEL	BATON ROUGE	LA	\$	378.00
ilti-Center, Randomized, Open Label Trial to Evaluate	NEDD	KHAN	GRAND RAPIDS	MI	\$	3,575.00
erum Hepcidin Levels to Predict Response to Oral or IV					l l	
	NEDD	KHAN	GRAND RAPIDS	м	s	903.00
,					Ť	
					l l	
ric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin					l l	
				FL TN		13,042.00
	DIXIT	SHANKER	LAS VEGAS	NV	\$:	12,240.00
						4,742.00 5,490.00
	GUNAWARDANE	RUWANI	FULTON	MD	\$	1,888.00
	HIDALGO MANDELL	GONZALO	ALEXANDRIA ROCK HILL	LA sc	\$	9,048.00
	DAA2	JULIETTE	SPARTANBURG	SC	\$	7,839.00
						6.561.00
	DOHMEIER	CARMEN	GREENSBORO	NC	\$	3,570.00
					\$	3,050.00
	KALMADI	SUJITH	CHANDLER	AZ	\$	120.00
ulti-Center, Randomized, Open Label Trial to Evaluate	SHTIVELBAND	MIKHAIL	CHANDLER	AZ	\$	870.00
erum Hepcidin Levels to Predict Response to Oral or IV					l l	
	VALMADI	CHITH	CHANDLED	47	e	210.00
ilti-Center, Randomized, Open Label Trial to Evaluate	OLIVIADI	301111	CHANDLER	AL.	3	210.00
erum Hepcidin Levels to Predict Response to Oral or IV					ı	
njectafer- vs. Int	SHTIVELBAND	MIKHAIL	CHANDLER	AZ	\$	420.00
dti.Center Randomized Onen Label Trial to Evaluate					\$	1,800.00
erum Hepcidin Levels to Predict Response to Oral or IV					l l	
are the Safety, Effect on Quality of Life and Resource	CAMPAU	HTTAIDDA	KANONA II I F	Tax	r.	50.00
		TERESA	THOMASVILLE	GA		15,537.50
					\$	8,400.00
dy to Investigate the Efficacy and Safety of Injectafer-					ı	
maltose- in the Treatment of Restless Legs Syndrome -					L	
	ADAMS	Mark	LUNDON	KY	\$	1,042.20 8,400.00
					l l	
MPARED TO SUMATRIPTAN NASAL SPRAY AND						
				MD	١	
MPARED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry	PETERLIN NEU	BARBARA ALICIA	BALTIMORE BALTIMORE	MD	\$	31,125.00 400.00
MPARED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry liti-Center, Randomized, Open Label Trial to Evaluate	PETERLIN NEU			MD	\$	31,125.00 400.00
MPARED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry Ill-Center, Randomized, Open Label Trial to Evaluate erum Hepdidin Levels to Predict Response to Oral or IV	PETERUN NEU			MD	\$	31,125.00 400.00
MPARED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry till Ecenter, Randomized, Open Label Trial to Evaluate erum Hepcidin Levels to Predict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource injectafer-vs. Interpetation-	PETERLIN NEU SUH			MD IL	\$	31,125.00 400.00 289.00
MPARED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry It Centery, Randomized, Open Label Trial to Evaluate erum Hepcidin Levels to Predict Response to Oral or IV are the Safety, Effect on Quality of Use and Resource injectafer-vs. Int Multi-center, Randomized, Double-blinded, Controlled	NEU	ALICIA	BALTIMORE	MD IL	\$	400.00
MPARED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry diff-center, Randomized, Open Label Trial to Evaluate runn Hepdidin Levels to Predict Response to Oral or IV are the Safely, Effect on Quality of Itle and Resource injectafer. vs. Int Multi-center, Randomized, Double-blinded, Controlled igate the Efficacy and Safely of Injectafer -ferric elipication. In Patients with Cancer- elipication - In Patients with Cancer- elipication - In Patients with Cancer- elipication.	NEU SUH	ALICIA JASON	BALTIMORE	MD IL	\$	289.00
WARAED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry diff-Center, Randomized, Open Label Trial to Evaluate rum Hepcidin Levels to fredict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource injectafer-vs. In Multi-center, Randomized, Double-blinded, Controlled igate the Efficacy and Safety of InjectaferFerric e injection- in Patients with Cancer- and restlated Anemia	NEU SUM	AUCIA JASON JASON	BALTIMORE JOLIET	IL IL IL	\$	289.00 7,647.00
MPARED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry till-Center, Randomized, Open Label Trial to Evaluate rum Hepcidin Levels to Predict Response to Oral or try are the Safety, Effect on Quality of Life and Resource necessary. The Commission of the Commission of the prediction vs. in the label the Efficacy and Safety of injectaferderric elipication - in Raients with Cancer- and crelated Anemia	NEU SUH	ALICIA JASON	BALTIMORE	IL IL IL NC	\$	289.00
MPARED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry Ill-Center, Randomized, Open Label Trial to Evaluate rurum Hepcidin Levels to Predict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource injectater vs. Int Multis-center, Randomized, Double-blinded, Controlled gapte the Efficacy and Safety of Injectaterterric enjection- in Fatients with Cancer- and related Anemia.	SUH SUH	AJICIA JASON JASON JASON	JOJET JOUET	IL IL IL NC	\$	289.00 7,647.00 9,206.25
MPARED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry Illi-Center, Randomized, Open Label Trial to Evaluate rurum Hepcidin Levels to Predict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource neglectairer vs. Int Multis-center, Randomized, Double-blinded, Controlled gapte the Efficacy and Safety of Injectualerlerric englection- in Fathents with Cancer- and residence and residence of the Controlled gapte the Efficacy and Safety of Injectualer	SUH SUH	AJICIA JASON JASON JASON	JOJET JOUET	IL I	\$	289.00 7,647.00 9,206.25
MARAED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry dit-Center, Randomized, Open Label Trial to Evaluate rum Hepcidin Levels to fredict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource injectafer -v., In: Multi-center, Randomized, Double-blinded, Controlled gate the Efficacy and Safety of Injectaferferric e injection- in Patients with Cancer- and related Anemia Multi-center, Randomized, Open-label, Controlled igate the Fficacy Server of Microscopic of Intravenous Multi-center, Randomized, Open-label, Controlled igate the Treatment Response of Intravenous	SUH SUH SUH MARKILEY	AJICIA JASON JASON JASON	BALTIMORE JOUET JOUET JOUET KINSTON	IL IL IL IL NC	\$	289.00 7,647.00 9,206.25 75.00
MPARED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE VIC Registry III- Center, Randomized, Open Label Trial to Evaluate run Hepcidin Levels to Predict Response to Oral or IV and the Control of the Control	SUH SUH	AJICIA JASON JASON JASON	JOJET JOUET	IL IL IL NC NC	\$	289.00 7,647.00 9,206.25
MARAED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry tils Center, Randomized, Open Label Trial to Evaluate rum Hepcidin Levels to Predict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource injectairer vs. Int. Multi-center, Randomized, Double-blinded, Controlled igate the Efficacy and Safety of Injectaferferric eliopetion- in Patients with Cancer- and re-related Anemia Multi-center, Randomized, Open-label, Controlled igate the Treatment Response of Intravenous ric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin sts with Iron deficient Anemia 1 Double-Billind, Multi-Center, Randomized, Plazebo- y to investigate the Efficacy and Safety of Injectafer-	SUH SUH SUH MARKILEY	AJICIA JASON JASON JASON	BALTIMORE JOUET JOUET JOUET KINSTON	IL IL IL INC NC	\$	289.00 7,647.00 9,206.25 75.00
MARAED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry tils Center, Randomized, Open Label Trial to Evaluate rum Hepcidin Lests to Predict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource injectater vs. Int. Multi-center, Randomized, Double-blinded, Controlled agate the Efficacy and Safety of Injectaferferric restated Anemia Multi-center, Randomized, Open-label, Controlled agate the Testement Response of Intravenous ric Carbonymaltose vs. Oral Iron to Baseline Hepcidin sts with Iron deficient Anemia 1 Double-Billind, Multi-Center, Randomized, Placebo- dy to Investigate the Efficacy and Safety of Injectafer- maltose- in the Treatment of Restless Legs Syndrome -	SUH SUH SUH MARKILEY	AJICIA JASON JASON JASON	BALTIMORE JOUET JOUET JOUET KINSTON	IL IL IL IL IL NC	\$	289.00 7,647.00 9,206.25 75.00
MARAED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry tils Center, Randomized, Open Label Trial to Evaluate trum Hepcidin Levels to Predict Response to Oral or IV are the Salety, Effect on Quality of Life and Resource necessary of the Commission of the Commission of the necessary of the trick of the Commission of the lepication - In Balents with Cancer - and related Anemia Multi-center, Randomized, Open-label, Controlled igate the Treatment Response of Intravenous ric Carbonymaltose - vs. Oral Iron to Baseline Hepcidin st with Iron deficient Anemia 1 Double-Billind, Multi-Center, Randomized, Placebo- Ty to Investigate the Efficacy and Salety of Injectater - nations in the Treatment Response of Injectater - nations in the Treatment Response of Injectater - nations in the Treatment Residency - nations in the Treatment Residency - Not the - - - - - - - - - - - - -	SUH SUH AAROLLEY MARILLEY	JASON JASON JASON JASON JASON Mark	BALTIMORE JOUET JOUET JOUET RINSTON	IL IL IL NC	\$	289.00 7,647.00 9,206.25 75.00 6,358.00
MARAED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry tils Center, Randomized, Open Label Trial to Evaluate rum Hepcidin Lests to Predict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource injectater vs. Int. Multi-center, Randomized, Double-blinded, Controlled agate the Efficacy and Safety of Injectaferferric restated Anemia Multi-center, Randomized, Open-label, Controlled agate the Testement Response of Intravenous ric Carbonymaltose vs. Oral Iron to Baseline Hepcidin sts with Iron deficient Anemia 1 Double-Billind, Multi-Center, Randomized, Placebo- dy to Investigate the Efficacy and Safety of Injectafer- maltose- in the Treatment of Restless Legs Syndrome -	SUH SUH SUH SUH SUH SUH SUH MARRILLEY MARRILLEY	AJCIA JASON JASON JASON Mark Mark	BALTIMORE JOUET JOUET JOUET KINSTON KINSTON	IL IL IL NC	\$	289.00 7.647.00 9.206.25 75.00 6.358.00
MARAED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry tilt-Center, Randomized, Open Label Trial to Evaluate rurn Hepcidin Levels to Predict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource injectaire - vs. Int. Multi-center, Randomized, Double-blinded, Controlled agate the Efficacy and Safety of Injectaferferric einjection- in Patients with Cancer- and -restated Anemia Multi-center, Randomized, Open-label, Controlled agate the Testament Response of Intravenous ric Carbonymaltose - vs. Oral Iron to Baseline Hepcidin stay with road Resident Anemia 1 Double-Bind, Multi-Center, Randomized, Plazebo- dy to Investigate the Efficacy and Safety of Injectafer- maltose- in the Treatment of Restless Legs Syndrome- Double-Bindin, Multi-Center, Randomized, Plazebo- dy to Investigate the Efficacy and Safety of Injectafer- maltose- in the Treatment of Restless Legs Syndrome- maltose- in the Treatment of Restless Legs Syndrome- maltose- in the Treatment of Restless Legs Syndrome-	SUH SUH MARILLEY MARILLEY MARILLEY	AUCIA JASON JASON JASON Mark Mark Mark	BALTIMORE JOUET JOUET JOUET FORET KINSTON KINSTON	IL IL IL NC	\$ \$ \$ \$	289.00 7,647.00 9,206.25 75.00 6,358.00 4,200.00
MARAED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry tilt-Center, Randomized, Open Label Trial to Evaluate rum Hepddin Levels to Predict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource injectafer vs. Int. Multi-center, Randomized, Double-blinded, Controlled igate the Efficacy and Safety of Injectaferderric e Injection- in Patients with Cancer- and -related Anemia Multi-center, Randomized, Open-label, Controlled igate the Prestment Response of Init zwenous ric Carbowynalized- vs. Oral Iron to Isaseline Hepcidin ss with Iron delicient Anemia The Carbowynalized of the Prestment Response of Init zwenous response of the Prestment of Restless Legs Syndrome - Double-Billind, Multi-Center, Randomized, Placebo y to Investigate the Efficacy and Sarety of Injectafer- maltose- in the Treatment of Restless Legs Syndrome - Multi-center, Randomized, Double-bilinded, Controlled	SUH SUH SUH SUH SUH SUH SUH MARRILLEY MARRILLEY	AJCIA JASON JASON JASON Mark Mark	BALTIMORE JOUET JOUET JOUET KINSTON KINSTON	IL IL IL NC	\$ \$ \$ \$ \$ \$ \$	289.00 7.647.00 9.206.25 75.00 6.358.00
MPARED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry tils Center, Randomized, Open Label Trial to Evaluate trum Hepcidin Levels to Predict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource injectater vs. Int. Multis-center, Randomized, Double-blinded, Controlled againe the Efficacy and Safety of Injectaterberric treated Annenia Wultis-center, Randomized, Open-label, Controlled agate the Treatment Response of Intravenous ric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin sts with Iron deficient Anemia 1 Double-Blind, Multi-Center, Randomized, Placebo ty to Investigate the Efficacy and Safety of Injectater- maltose- in the Treatment of Restless Legs Syndrome- Double-Blind, Miccenter, Placebo dy to Investigate the Efficacy and Safety of Injectater- maltose- in the Treatment of Restless Legs Syndrome- Double-Blind, Miccenter, Randomized, Placebo dy to Investigate the Efficacy and Safety of Injectater- maltose- in the Treatment of Restless Legs Syndrome- Multi-center, Randomized, Double-Blind, Angel Agraety Multi-center, Randomized, Double-Blinded, Controlled agate the Efficacy and Safety of Injectater british Carter, Randomized, Controlled agate the Efficacy and Safety of Injectater british Carter, Randomized, Controlled agate the Efficacy and Safety of Injectater british Carter, Placebo	SUH SUH MARILLEY MARILLEY MARILLEY	AUCIA JASON JASON JASON Mark Mark Mark	BALTIMORE JOUET JOUET JOUET FORET KINSTON KINSTON	IL IL IL NC	\$ \$ \$ \$ \$ \$ \$	289.00 7,647.00 9,206.25 75.00 6,358.00 4,200.00
MARAED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry tils Center, Randomized, Open Label Trial to Evaluate trum Hepcidin Levels to Predict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource injectaier vs. Init. Multis-center, Randomized, Double-blinded, Controlled againe the Efficacy and Safety of InjectaferFerric enjection- in Patients with Cancer- and verlated Annelia Multis-center, Randomized, Open-label, Controlled agate the Treatment Response of Intravenous ric Carbonymaltose- vs. Oral Iron to Baseline Hepcidin sts with ron deficient Anemia 1 Double-Blind, Multi-Center, Randomized, Placebo- dy to Investigate the Efficacy and Safety of Injectafer- maltose- in the Treatment of Residess Legs Syndrome- Double-Blind, Multi-Center, Randomized, Placebo- dy to Investigate the Efficacy and Safety of Injectafer- maltose- in the Treatment of Residess Legs Syndrome- Double-Blind, Multi-Center, Randomized, Placebo- dy to Investigate the Efficacy and Safety of Injectafer- maltose- in the Treatment of Residess Legs Syndrome- Multi-center, Randomized, Double-Blinded, Controlled agate the Efficacy and Safety of Injectafer- erric enjection- in Patients with Cancer- and re-related Anemia	SUH SUH MARILLEY MARILLEY MARILLEY	AUCIA JASON JASON JASON Mark Mark Mark	BALTIMORE JOUET JOUET JOUET FORET KINSTON KINSTON	IL IL IL NC	\$ \$ \$ \$ \$ \$ \$	289.00 7,647.00 9,206.25 75.00 6,358.00 4,200.00
MPARED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE TRIC Registry Itil: Center, Randomized, Open Label Trial to Evaluate run Hepcidin Levels to Predict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource Multi-center, Randomized, Double-Linded, Controlled igate the Efficacy and Safety of Injectafer - Ferric lepiction- In Pasients with Cancer- and -related Anemia Multi-center, Randomized, Open-label, Controlled igate the Treatment Response of Intravenous ric Carboxymalione- vs. Oral front to Baseline Hepcidin Double-Billind, Multi-Center, Randomized, Placebo Double-Billind, Multi-Center, Randomized, Spacebo Multi-center, Randomized, Double-billinded, Controlled igate the Efficacy and Safety of Injectafer- matoca- in the Terestment of Restless Leg Syndrome Multi-center, Randomized, Double-billinded, Controlled igate the Efficacy and Safety of Injectafer- related Anemia	SUH SUH MARRILEY MARRILEY MARRILEY MARRILEY MARRILEY MARRILEY MATSON	AUCIA JASON JASON JASON Mark Mark Mark PETER PETER	BALTIMORE JOUET JOUET JOUET RINSTON KINSTON KINSTON KINSTON	IL IL IL NC	\$ \$ \$ \$ \$ \$ \$	289.00 7,647.00 9,206.25 75.00 6,358.00 4,200.00 567.00 16,716.00
MARAED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry tils Center, Randomized, Open Label Trial to Evaluate trum Hepcidin Levels to Predict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource injectaier vs. Init. Multis-center, Randomized, Double-blinded, Controlled againe the Efficacy and Safety of InjectaferFerric enjection- in Patients with Cancer- and verlated Annelia Multis-center, Randomized, Open-label, Controlled agate the Treatment Response of Intravenous ric Carbonymaltose- vs. Oral Iron to Baseline Hepcidin sts with ron deficient Anemia 1 Double-Blind, Multi-Center, Randomized, Placebo- dy to Investigate the Efficacy and Safety of Injectafer- maltose- in the Treatment of Residess Legs Syndrome- Double-Blind, Multi-Center, Randomized, Placebo- dy to Investigate the Efficacy and Safety of Injectafer- maltose- in the Treatment of Residess Legs Syndrome- Double-Blind, Multi-Center, Randomized, Placebo- dy to Investigate the Efficacy and Safety of Injectafer- maltose- in the Treatment of Residess Legs Syndrome- Multi-center, Randomized, Double-Blinded, Controlled agate the Efficacy and Safety of Injectafer- erric enjection- in Patients with Cancer- and re-related Anemia	SUH SUH MARRILEY MARRILEY MARRILEY MARRILEY MARRILEY MARRILEY MATSON	AUCIA JASON JASON JASON Mark Mark Mark PETER PETER	BALTIMORE JOUET JOUET JOUET RINSTON KINSTON KINSTON KINSTON	IL IL IL NC	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,200.00 289.00 7,647.00 9,206.25 75.00 6,358.00 4,200.00 567.00 16,716.00 340.10
MPARED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry tils Center, Randomized, Open Label Trial to Evaluate trum Repcidin Levels to Predict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource Multi-center, Randomized, Double-lained, Controlled igate the Efficacy and Safety of Injectafer - Ferric legicton- in Patients with Cancer- and related Anemia Multi-center, Randomized, Open-label, Controlled igate the Trestment Response of intravenous ric Carbonyniatiose - vs. Oral fron to Dasseline Hepcidin so with Industrial Controlled Anemia Multi-center, Randomized, Open-label, Controlled igate the Trestment Response of intravenous tric Carbonyniatiose - vs. Oral fron to Dasseline Hepcidin so with Industrial Controlled Anemia Multi-center, Randomized, Placebo dy to Investigate the Efficacy and Safety of Injectafer- matioca- in the Teratment of Restless Legs Syndrome Double-Blind, Multi-Center, Randomized, Placebo dy to Investigate the Efficacy and Safety of Injectafer- matioca- in the Teratment of Restless Legs Syndrome Multi-center, Randomized, Double-Blinded, Controlled igate the Efficacy and Safety of Injectafer - Ferric einjection- in Patients with Cancer- and related Anemia Multi-center, Randomized, Double-Blinded, Controlled igate the Efficacy and Safety of Injectafer - Serric einjection- in Patients with Cancer- and ericlated Anemia	SUH SUH MARRILEY MARRILEY MARRILEY MARRILEY MARRILEY MARRILEY MATSON	AUCIA JASON JASON JASON Mark Mark Mark PETER PETER	BALTIMORE JOUET JOUET JOUET RINSTON KINSTON KINSTON KINSTON	IL IL IL NC	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	289.00 7,647.00 9,206.25 75.00 6,358.00 4,200.00 567.00 16,716.00
MPARED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry tils Center, Randomized, Open Label Trial to Evaluate trum Repcidin Levels to Predict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource Multi-center, Randomized, Double-lainded, Controlled igate the Efficacy and Safety of Injectafer - Ferric legicton- in Patients with Cancer- and related Anemia Multi-center, Randomized, Open-label, Controlled igate the Trestment Response of Intravenous ric Carbonyniatiose - vs. Oral fron to Dasseline Hepcidin so with Index Section of Patients of Intravenous ric Carbonyniatiose - vs. Oral fron to Dasseline Hepcidin so with Index Section Annual American matter of the Section of Intravenous dy to Investigate the Efficacy and Safety of Injectafer- mattoce- in the Teratement of Restless Legs Syndrome Double-Blind, Multi-Center, Randomized, Placebo dy to Investigate the Efficacy and Safety of Injectafer- mattoce- in the Teratement of Restless Legs Syndrome Multi-center, Randomized, Double-Blinded, Controlled igate the Efficacy and Safety of Injectafer - Ferric einjection- in Patients with Cancer- and related Anemia Multi-center, Randomized, Double-Blinded, Controlled igate the Efficacy and Safety of Injectafer - Service ignetic the Efficacy and Safety of Injectafer - Service ignetic the Efficacy and Safety of Injectafer - Service ignetic in England with Cancer- and	SUH SUH SUH MARILLEY MARRILLEY MARRILLEY MARRILLEY MARSON WATSON	AUCIA JASON JASON JASON JASON Mark Mark Mark PETER PETER PETER	BALTIMORE JOUET JOUET JOUET JOUET JOUET JOUET KINSTON KINSTON KINSTON KINSTON KINSTON KINSTON	IL IL IL NC	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,200.00 289.00 7,647.00 9,206.25 75.00 6,358.00 4,200.00 567.00 16,716.00 340.10
MARAED TO SUMATRIPTAN NASAL SPRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry till: Center, Randomized, Open Label Trial to Evaluate trum Repcidin Levels to Predict Response to Oral or IV are the Salety, Effect on Quality of Life and Resource injectader- s.m. interpretation of the Controlled igate the Efficacy and Salety of Injectaferferric injection- in Patients with Cancer- and related Anemia Multi-center, Randomized, Open-label, Controlled igate the Treatment Response of Intravenous ric Carboxymaltose- w. Oral Iron to Baseline Hepcidin ts with Iron deficient Anemia 1 Double-Blind, Multi-Center, Randomized, Placebo IV to Investigate the Efficacy and Salety of Injectafer- maltose- in the Treatment of Restless Legs Syndrome- Double-Blind, Multi-Center, Randomized, Placebo Dy to Investigate the Efficacy and Salety of Injectafer- maltose- in the Treatment of Restless Legs Syndrome- Double-Blind, August Salety of Injectafer- maltose- in the Treatment of Restless Legs Syndrome- Double-Blind, August Salety of Injectafer- maltose- in the Treatment of Restless Legs Syndrome- Double-Blind, August Salety of Injectafer- enablose- in the Treatment of Restless Legs Syndrome- Multi-center, Randomized, Double-Blinded, Controlled igate the Efficacy and Salety of Injectafer- eristlest Anemia Multi-center, Randomized, Double-Blinded, Controlled igate the Treatment Response of Intravenous	SUH SUH SUH MARILLEY MARRILLEY MARRILLEY MARRILLEY MARSON WATSON	AUCIA JASON JASON JASON JASON Mark Mark Mark PETER PETER PETER	BALTIMORE JOUET JOUET JOUET JOUET JOUET JOUET KINSTON KINSTON KINSTON KINSTON KINSTON KINSTON	IL IL NC	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,200.00 289.00 7,647.00 9,206.25 75.00 6,358.00 4,200.00 567.00 16,716.00 340.10
MARAED TO SUMATRIPTAN NASAL SPIRAY AND THE ACUTE ABORTIVE TREATMENT OF MIGRAINE tric Registry tils Center, Randomized, Open Label Trial to Evaluate trum Hepcidin Levels to Predict Response to Oral or IV are the Safety, Effect on Quality of Life and Resource injectater vs. Int. Multi-center, Randomized, Double-blinded, Controlled agate the Efficacy and Safety of Injectaferferric enjection- in Patients with Cancer- and restlated Annelia Multi-center, Randomized, Open-label, Controlled agate the Treatment Response of Intravenous ric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin ts with Iron deficient Annelia -1 Double-Blind, Multi-Center, Randomized, Placebo- dy to investigate the Efficacy and Safety of Injectafer- maltose- in the Treatment of Restless Legs Syndrome- Double-Blind, Multi-Center, Randomized, Placebo- dy to investigate the Efficacy and Safety of Injectafer- maltose- in the Treatment of Restless Legs Syndrome- Double-Blind, Multi-Center, Randomized, Placebo- dy to investigate the Efficacy and Safety of Injectafer- maltose- in the Treatment of Restless Legs Syndrome- Multi-center, Randomized, Double-blinded, Controlled agate the Efficacy and Safety of Injectafer- recrized Annelia Multi-center, Randomized, Double-blinded, Controlled agate the Efficacy and Safety of Injectafer- recrized and Safety of Injectafe	SUH SUH SUH MARILLEY MARRILLEY MARRILLEY MARRILLEY MARSON WATSON	AUCIA JASON JASON JASON JASON Mark Mark Mark PETER PETER PETER	BALTIMORE JOUET JOUET JOUET JOUET JOUET JOUET KINSTON KINSTON KINSTON KINSTON KINSTON KINSTON	IL IL NC	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,200.00 289.00 7,647.00 9,206.25 75.00 6,358.00 4,200.00 567.00 16,716.00 340.10
e an Edn Nick-ulle an Ulle an Ulle an Edn Edn P	ire the Safety, Effect on Quality of Life and Resource Josephan Processor Services of the Controlled gate the Efficacy and Safety of Injectator - Gate Gate Gate Gate Gate Gate Gate Gate	run Hepotioni Levels to Predict Response to Oral or V rethe Safety, Effect on Quality of Uffer and Resource jectafer v.v. Int OUTER GUTER G	The besider, left on Quality of Life and Resource (Carther Landonised, Placebotter) with the Service of the Carther Landonised, Placebotter (Carther Landonised, Placebotter) (Carther Landonised, Placebotter) (Carther Landonised, Placebotter) (Carther Landonised, Double-blinded, Controlled gast the Efficacy and Safety of Injectafer - ferric injection in Patients with Carther - and Carther Landonised, Double-blinded, Controlled gast the Efficacy and Safety of Injectafer - ferric injection in Patients with Carther - and Carther Landonised, Double-blinded, Controlled gast the Efficacy and Safety of Injectafer - ferric injection in Patients with Carther - and Carther Landonised, Double-blinded, Controlled gast the Efficacy and Safety of Injectafer - service in	um heyodic Levels to Predict Reports to Oral or IV es Safer, Effect on Quality of the and Resource guide the Efficiary and Safery of Injectater- vallouse in the Teachment of Resides Legis Syndrome ODMMEER CAMMIN OSAMA OSAM	usin Regulation Levels to Predict Response to Cut of V Executed Section (Control of the Control of	MATERIAL CONTROLLED FOR THE ADDRESS OF THE OF THE ADDRESS OF THE

				•		
Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled					
	Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin					
MARK LAMET MD PA	Levels in Patients with Iron deficient Anemia -I	LAMET	Mark	HOLLYWOOD	FL	\$ 198.29
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled					
	Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin					i
Mary Hitchcock Memorial Hospital MASSACHUSETTS GENERAL HOSPITAL	Levels in Patients with Iron deficient Anemia -I 1VIT14037	SIEGEL WINKELMAN	JOHN JOHN	LEBANON BOSTON	NH MA	\$ 16,685.00
	1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer-					
	Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome -					
MASSACHUSETTS GENERAL HOSPITAL MAYO CLINIC HOSPITAL	RLS- 1VIT14037	WINKELMAN DRIVER-DUNCKLEY	JOHN ERIKA	BOSTON SCOTTSDALE	MA AZ	\$ 10,390.00 \$ 14,500.00
	1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV					
	iron and Compare the Safety, Effect on Quality of Life and Resource			JUPITER		
MEDICAL CONSULTANTS MANAGEMENT, LLC	Utilization, of Injectafer- vs. Int	RABIEI	ABBAS	JUPITER	PL .	\$ 45.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous					i
Medical Research Center of CT	Injectafer - Ferric Carboxymaltose - vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -I	GINSBURG	PHILIP	HAMDEN	CT	\$ 3,178.00
MEGHANA DORESWAMY	1VIT14037				CI	\$ 8,400.00
METHODIST HOSPITAL MICHAEL LEDET	1VIT14037 1VIT14037	ONDO	WILLIAM	HOUSTON	TX	\$ 23,595.00 \$ 4,200.00
	1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectaferferric					1
MICHIANA HEMATOLOGY-ONCOLOGY P C	carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	BRAUN	EDUARDO	SOUTH BEND	IN	\$ 13,704.10
INICIDATA TEMATOLOGY CHECKOGY C	1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer ferric	DISSON.	EDUNIO	300 HI DENO		3 13,704.10
	carboxymaltose injection- in Patients with Cancer- and					1
MICHIANA HEMATOLOGY-ONCOLOGY, P.C. MID-ILLINOIS HEMATOLOGY ONCOLOGY ASSOCIATES LTD	Chemotherapy-related Anemia 1VIT14039	BRAUN MIGAS	EDUARDO JOHN	SOUTH BEND NORMAL	IN II	\$ 630.00
	1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectaferferric					
	carboxymaltose injection- in Patients with Cancer- and					1
MID-ILLINOIS HEMATOLOGY ONCOLOGY ASSOCIATES LTD MILTON S. HERSHEY MEDICAL CENTER		MIGAS WASSNER	JOHN STEVEN	NORMAL HERSHEY	IL PA	\$ 7,647.00 \$ 600.00
MOHAMMED BARI	1VIT14037 1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo-					\$ 8,400.00
	Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome -					in .
MOHAMMED BARI, M.D. INC	RLS-	BARI	MOHAMMED	NATIONAL CITY	CA	\$ 20,238.00
MONTEFIORE MEDICAL CENTER	1VIT14039	Chaitowitz	Mark	NEW YORK	NY	\$ 11,753.90
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous					i
	InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin					
NASHVILLE SURGICAL ASSOCIATES, PLLC NEUROLOGY OFFICES OF SOUTH FLORIDA PLLC	Levels in Patients with Iron deficient Anemia -I 1VIT14037	PRUITT FERREIRA	RONALD MICHELLE	NASHVILLE BOCA RATON	FL	\$ 567.00 \$ 6,761.00
	1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer - ferric					1
NORTH MISSISSIPPI HEMATOLOGY & ONCOLOGY ASSOC.	carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	HILL	JULIAN	TUPELO	MS	\$ 9,020.00
NORTH MISSISSIPPI MEDICAL CENTER	1VIT14039 1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate	HILL	JULIAN	TUPELO	MS	\$ 45,898.00
	the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV					1
NORTH MISSISSIPPI MEDICAL CENTER, INC	iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer- vs. Int	HILL	JULIAN	TUPELO	MS	\$ 420.00
	1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectaferferric					1
NORTH MISSISSIPPI MEDICAL CENTER, INC	carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	BIII	JULIAN	TUPELO	MC	\$ 5,900.00
NORTH WISSISSIFFI WEDICAE CENTER, INC	1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate	THEE	JOLIAN	TOPELO	IVIS	3 3,500.00
	the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV iron and Compare the Safety, Effect on Quality of Life and Resource					i
NORTH SHORE UNIVERSITY HOSPITAL HOMECARE	Utilization, of Injectafer- vs. Int	SWAMINATH	ARUN	NEW YORK	NY	\$ 45.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled					1
	Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin					i
NORTHWEST GASTROENTEROLOGY ASSOCIATES, INC., P.S NORTON HEALTHCARE	Levels in Patients with Iron deficient Anemia -I 1VIT13032	WOHLMAN HOW	ROBERT HELEN	LOUISVILLE	WA KY	\$ 378.00 \$ 2,165.00
	1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV					
NORTON HEALTHCARE	iron and Compare the Safety, Effect on Quality of Life and Resource	HOW	HELEN	CHICAGO		\$ 1,500.00
NONTON TEXETTORE	Utilization, of Injectafer- vs. Int	now	HEELN	CHICAGO	IL.	3 1,300.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous					i
NOVANT MEDICAL GROUP INC	InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -I	WILSON	JASON	HUNTERSVILLE	NC	\$ 1,400.00
OCEAN BLUE MEDICAL RESEARCH CENTER, INC		TERRELONGE	ANTONIO	MIAMI	FL	\$ 20,955.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled					i
	Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin					1
OCEAN BLUE MEDICAL RESEARCH CENTER, INC	Levels in Patients with Iron deficient Anemia -I	TERRELONGE	ANTONIO	MIAMI	FL	\$ 378.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous					i
	InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin					1
Ohio State University Hospital OMEGA RESEARCH	Levels in Patients with Iron deficient Anemia -I 1VIT13032	ZHANG Nair	CHENG Santosh	ORANGE CITY	OH FL	\$ 4,200.00 \$ 3,080.00
ONCOLOGY HEMATOLOGY	1VIT14039 1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled	BAJAJ	MADHURI	PEORIA	IL	\$ 13,822.00
	Study to Investigate the Efficacy and Safety of Injectaferferric carboxymaltose injection- in Patients with Cancer- and					i
ONCOLOGY-HEMATOLOGY ASSOCIATES OF CENTRAL ILLIN ORCHARD HEALTHCARE	Chemotherapy-related Anemia 1/1/113032	BAJAJ	MADHURI IRA	PEORIA SKOKIE	IL.	\$ 567.00 \$ 2.660.00
PAUL WYLIE	1VIT14037				IL	\$ 7,000.00
PHARMASEEK FINANCIAL SERVICES LLC PHARMASEEK FINANCIAL SERVICES LLC	1VIT14037 1VIT14037	GOETTING KRAINSON	Mark JAMES	PORTAGE MIAMI	MI FL	\$ 5,742.00 \$ 5,742.00
PHARMASEEK FINANCIAL SERVICES LLC PHARMASEEK FINANCIAL SERVICES LLC	1VIT14037 1VIT14039	NGUYEN BARRANCO	CHRISTINA ELIZABETH	GARDEN GROVE PONCE	CA PR	\$ 5,742.00 \$ 6,742.00
PHARMASEEK FINANCIAL SERVICES LLC PHARMASEEK FINANCIAL SERVICES LLC	1VIT14039 1VIT14037 A Double-Blind, Multi-Center, Randomized, Placebo-	Santiago-Guzman	Edgardo	San Juan	PR PR	\$ 8,191.50
	Controlled Study to Investigate the Efficacy and Safety of Injectafer					i
PMC PHYSICIAN NETWORK	Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	MANDELL	HOWARD	ROCK HILL	sc	\$ 9,717.00
PREFERRED RESEARCH	1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate	WYLIE	PAUL	LITTLE ROCK	AR	\$ 23,775.60
	the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV iron and Compare the Safety, Effect on Quality of Life and Resource					i
PROFESSIONAL PAIN MANAGEMENT CLINIC INC	Utilization, of Injectafer- vs. Int	GERSHENBAUM	BART	DAVIE	FL	\$ 50.00
RAKESH GAUR	1VIT14037					\$ 3,300.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous					i
RALEIGH DURHAM MEDICAL GROUP PA	Injectafer Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -I	RUTLAND	TRAVIS	DOTHAN	Al	\$ 13,650.00
RALEIGH DURHAM MEDICAL GROUP PA REGINAL CANCER CARE ASSOCIATION	1VIT14039	RUTLAND BOCCIA	TRAVIS RALPH	BETHESDA BETHESDA	MD MD	\$ 13,650.00 \$ 1,107.00
	1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer-					i
RIVERSIDE/SAN BERNARDINO COUNTY INDIAN HEALTH, IN	Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	Anderson	Donald	Redlands	CA	\$ 7,000.00
ROBERT DRODER	1VIT14039 1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled					\$ 14,080.00
	Study to Investigate the Efficacy and Safety of Injectaferferric					i
ROPER SAINT FRANCIS PHYSICIANS NETWORK	carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	ORCUTT	JAMES	CHARLESTON	sc	\$ 7,710.00
-	1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer-					
CAAD LIDSTATE MELIDOLOGY D.A.	Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome -	SAAD	JULIETTE	CDADTAND/ IDC	sc	\$ 23.780.00
SAAD UPSTATE NEUROLOGY, P.A.	RLS- 1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled	3000	SOCIETE	SPARTANBURG	JC	23,/80.00 د
	Study to Investigate the Efficacy and Safety of Injectaferferric carboxymaltose injection- in Patients with Cancer- and					i
SAINT ANTHONY MEDICAL CENTER	Chemotherapy-related Anemia	SREENIVASAPPA	SHYLENDRA	ROCKFORD	IL	\$ 7,080.00

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous					
	InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin					
SAN ANTONIO GASTROENTEROLOGY ASSOCIATES, PA	Levels in Patients with Iron deficient Anemia -I 1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate	BULLOCK	JEFF	SAN ANTONIO	TX	\$ 3,500
	the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV iron and Compare the Safety, Effect on Quality of Life and Resource					
SANTEE HEMATOLOGY ONCOLOGY INC	Utilization, of Injectafer- vs. Int	CLOWNEY	BILLY	SUMTER	sc	\$ 378
	1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectaferferric					
SATISH A SHAH M.D. P.C.	carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	KHAIR	TINA	GETTYSBURG	PA	\$ 7.340
antiati et atieri, intagi i et	1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled	N. P. III.	1100	GETTISONG		7 7,540
	Study to Investigate the Efficacy and Safety of Injectafer ferric carboxymaltose injection - in Patients with Cancer - and					
SATISH A. SHAH, M.D., P.C. SE MISSOURI HOSPITAL	Chemotherapy-related Anemia 1VIT13032	SHAH MOSLEY	SATISH JAMES	GETTYSBURG CAPE GIRARDEAU	PA MO	\$ 567 \$ 1,240
SHANKER DIXIT	1VIT14037 1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo-	WOJELI	2 AVILLA	CHI E GIIONIDENO	ino	\$ 4,200
1	Controlled Study to Investigate the Efficacy and Safety of Injectafer					
SHANKER N DIXIT, MD PC	Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	DIXIT	SHANKER	LAS VEGAS	NV	\$ 9,717
J. D. H. L.			S. S. WILL	DO TOTO	11.0	3,717
1	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous					
SHREVEPORT ENDOSCOPY CENTER, A MEDICAL CORPORA	InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -I	JOHNSON	LAWRENCE	BOSSIER CITY	I A	\$ 2,800
SOLLY CHEDID	1VIT14039	John Son	D. WILLIAM C.	DOSSER CITT		\$ 7,080
1	1VIT13035- A Multi-center, Randomized, Open-label, Controlled					
	Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin					
SOUTH BROWARD HOSPITAL DISTRICT	Levels in Patients with Iron deficient Anemia -I	LAMET	Mark	HOLLYWOOD	FL	\$ 4,900
	1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV					
SOUTHEAST HOSPITAL BASED PHYSICIANS LLC	iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer- vs. Int	MOSLEY	JAMES	CAPE GIRARDEAU	мо	\$ 45.
300 TESOT TO STATE DIGES THIS CONTROL	1VIT14038- A Blinded, Randomized, Placebo-Controlled Study to	MOSEL	271112	CALL GIIDAIDEAU	MO.	7
	Investigate the Efficacy and Safety of InjectaferFerric Carboxymaltose- in the Treatment of Iron Deficient patients with					
SOUTHWEST UROLOGY, LLC SRSD INC.	Fibromyalgia.	BOOMERSHINE BARI	CHAD MOHAMMED	NASHVILLE NATIONAL CITY	TN CA	\$ 378 \$ 34,738
ST. JOSEPHS HOSPITAL & MEDICAL CTR	1VIT13032	UCAR	KALUST	GLENDALE	CA CA	\$ 1,750
STANFORD UNIVERSITY	Venofer Pediatric Registry 1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo-	WONG	CYNTHIA	STANFORD	LA	\$ 2,800
	Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome -					
SYNERGY THERAPY, LLC	RLS-	GUNAWARDANE	RUWANI	ELLICOTT CITY	MD	\$ 630
TAMPA GENERAL HOSPITAL	1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled	JAGLAL	MICHAEL	TAMPA	FL	\$ 16,876
	Study to Investigate the Efficacy and Safety of Injectaferferric carboxymaltose injection- in Patients with Cancer- and					
TAMPA GENERAL MEDICAL GROUP INC	Chemotherapy-related Anemia	JAGLAL	MICHAEL	TAMPA	FL	\$ 80
TANNAZ ARMAGHANY	1VIT14039					\$ 7,000
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous					
	InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin					
TENNESSEE ONCOLOGY PLLC TERESA COLEMAN	Levels in Patients with Iron deficient Anemia -I 1VIT14039	PRUITT	RONALD	NASHVILLE	TN	\$ 1,400 \$ 7,160
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled					
	Study to Investigate the Treatment Response of Intravenous					
TEXAS UROLOGY GROUP, PA	InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -I	BULLOCK	JEFF	SAN ANTONIO	TX	\$ 2,880
THE CENTER FOR GASTROINTESTINAL DISORDERS THE JONES CLINIC, PC	IVIT13035 1VIT13032	LAMET JONES	Mark CLYDE	HOLLYWOOD MEMPHIS	FL TN	\$ 61 \$ 2,100
THE JONES CLINIC, PC	1VIT13035	JONES	CLYDE	MEMPHIS	TN	\$ 2,750
1	1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer - ferric					
THE IONES CLINIC DC	carboxymaltose injection- in Patients with Cancer- and	IONIES	CIVIDE	ATLANTA	GA	6 21 210
THE JONES CLINIC, PC	Chemotherapy-related Anemia	JONES	CLYDE	ATLANTA	GA	\$ 21,210
THE JONES CLINIC, PC		JONES	CLYDE	ATLANTA	GA	\$ 21,210
	Chemotherapy-related Anemia 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carbowymathose- vs. Oral Iron to Baseline Hepcidin				GA OB	
THE JONES CLINIC, PC THE OREGON CLINIC PC THE POLYCLINIC	Chemotherapy-related Anemia 1VTI.3035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous InjectaferFarric Carbonymistors-v. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1 JVTI.4037	IONES GRUNKEMEIER DORESWAMY	CLYDE DAVID MEGHANA	ATLANTA PORTLAND SEATTLE	GA OR WA	\$ 21,210. \$ 378. \$ 33,109.
THE OREGON CLINIC PC	Chemotherapy-related Anemia 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectaferferric Carbooymaltose-vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT14037 1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo-	GRUNKEMEIER	DAVID	PORTLAND		\$ 378
THE OREGON CLINIC PC THE POLYCUNIC	Chemotherapy-related Anemia 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectaferferric Carboxymaltose-vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-I 3VIT14037 1VIT14037 A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carboxymatose- in the Treatment of Restless legs Syndrome-	GRUNKEMEIER DORESWAMY	DAVID MEGHANA	PORTLAND SEATTLE	WA	\$ 378.
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR.	Chemotherapy-related Anemia 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectaferferric Carbooymaltose-vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT14037 1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer Ferric Carbooymaltose- in the Treatment of Restless Legs Syndrome- RIS- 1VIT14038	GRUNKEMEIER	DAVID	PORTLAND		\$ 378 \$ 33,109 \$ 7,567 \$ 2,000
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR.	Chemotherapy-related Anemia 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-Ferric Carbooymaltose-vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I 1VIT14037 1VIT14037 - A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carbonymaltose- in the Treatment of Restless Legs Syndrome- RIS- 1VIT140337 1VIT140337 1VIT14037 - A Multi-center, Randomized, Double-blinded, Controlled	GRUNKEMEIER DORESWAMY DORESWAMY	DAVID MEGHANA MEGHANA	PORTLAND SEATTLE SEATTLE	WA	\$ 378 \$ 33,109 \$ 7,567
THE OREGON CLINIC PC	Chemotherapy-related Anemia 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-Aerric Carboxymaltose-vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 3VIT14037- 3VIT14037- ADuble-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectuler- renric Carboxymathose-in the Treatment of Resides Legs Syndrome- 3VIT14038- 1VIT14039- 1VIT14039- 1VIT14039- 1VIT14039- 1VIT14039- 1VIT14039- 1VIT14039- 1VIT14038- 1VIT	GRUNKEMEIER DORESWAMY DORESWAMY	DAVID MEGHANA MEGHANA	PORTLAND SEATTLE SEATTLE	WA	\$ 378 \$ 33,109 \$ 7,567 \$ 2,000
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR.	Chemotherapy-related Anemia 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-Ferric Carbooymaltose-vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I 1VIT14037 1VIT14037 - A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carbonymaltose- in the Treatment of Restless Legs Syndrome- RIS- 1VIT140337 1VIT140337 1VIT14037 - A Multi-center, Randomized, Double-blinded, Controlled	GRUNKEMEIER DORESWAMY DORESWAMY	DAVID MEGHANA MEGHANA	PORTLAND SEATTLE SEATTLE	WA	\$ 378 \$ 33,109 \$ 7,567 \$ 2,000
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN	Chemotherapy-related Anemia 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectaferferric Carbooymaltose-vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT14037 1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carbooymaltose- in the Treatment of Restless Legs Syndrome- RIS- 1VIT14033- 1VIT14033- 1VIT14033- 1VIT14034- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectaferferric carbooymaltose injection- in Patients with Cancer- and	GRUNKEMEER DORESWAMY DORESWAMY CHEDID	DAVID MECHANA MECHANA SOLLY	PORTLAND SEATTLE SEATTLE BELTON	WA	\$ 378 \$ 33,109 \$ 7,567 \$ 2,000 \$ 9,012
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN	Chemotherapy-related Anemia 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectaferferric Carbooymaltose-vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT14037 1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carbooymaltose- in the Treatment of Restless Legs Syndrome- RIS- 1VIT14033- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectaferferric carbooymaltos injection- in Patients with Cancer- and Chemotherapy-related Anemia 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Teratment Response of Intravenous	GRUNKEMEER DORESWAMY DORESWAMY CHEDID	DAVID MECHANA MECHANA SOLLY	PORTLAND SEATTLE SEATTLE BELTON	WA	\$ 378 \$ 33,109 \$ 7,567 \$ 2,000 \$ 9,012
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN	Chemotherapy-related Anemia 1VT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-Ferric Carboxymaltose-vs. Oral fron to Baseline Hepcidin Levels in Patients with fron deficient Anemia -1 1VT12037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carboxymaltose-in the Treatment of Restless Legs Syndrome- ILVT1038- 1VT11039- A Multi-center, Randomized, Double-blinded, Controlled 1VT1039-Investigate the Efficacy and Safety of Injectafer- carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia 1VT13035- A Multi-center, Randomized, Open-label, Controlled	GRUNKEMEER DORESWAMY DORESWAMY CHEDID	DAVID MECHANA MECHANA SOLLY	PORTLAND SEATTLE SEATTLE BELTON	WA	\$ 378 \$ 33,109 \$ 7,567 \$ 2,000 \$ 9,012
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA	Chemotherapy-related Anemia 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-ferric Carbooymaltose-vs. Oral fron to Baseline Hepcidin 1VIT13037-A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Selfey of Injectafer- Ferric Carbooymaltose- in the Treatment of Restless Legs Syndrome- 1SI- 1VIT14038- 1VIT14039- 1VIT14039-A Multi-center, Randomized, Double-Blinded, Controlled Study to Investigate the Efficacy and Selfey of Injectafer- Carbooymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Sudy to Investigate the Ferticany et Response of Intravenous Injectafer-ferric Carbooymaltose- vo. Oral fron to Baseline Hepcidin Levels in Patients with ron deficient Anemia -1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled	GRUNKEMEER DORESWAMY DORESWAMY CHEDID WATSON	DAVID MEGHANA MEGHANA SOLLY PETER	PORTLAND SEATTLE SEATTLE BEETON KINSTON	WA	\$ 378 \$ 33,109 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA	Chemotherapy-related Anemia 1VIT3035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-ferric Carbooymahiose-vs. Oral fron to Baseline Hepcidin Levels in Patients with Into ndeficient Anemia-1 1VIT2037 1VIT3037 A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carbooymahiose-in the Treatment of Restless Legs Syndrome- RIS- 1VIT3037 1VIT3037 1VIT3038-A Multi-center, Randomized, Double-Diinded, Controlled Study to Investigate the Efficacy and Safety of Injectaferferric carbooymahiose injection- in Patients with Cancer- and Chemotherapy related Anemia 1VIT3035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Teratment Response of Intravenous InjectaferFerric Carbooymahiose-v. Or all fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1 1VIT3035-A Multi-center, Randomized, Open-label, Controlled	GRUNKEMEER DORESWAMY DORESWAMY CHEDID WATSON	DAVID MEGHANA MEGHANA SOLLY PETER	PORTLAND SEATTLE SEATTLE BEETON KINSTON	WA	\$ 378 \$ 33,109 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA	Chemotherapy-related Anemial 1VIT3035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-ferric Carbooymahiose-vs. Oral fron to Baseline Hepcidin Levels in Patients with Into ndeficient Anemia-1 1VIT2037 1VIT3037-A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carbooymahiose-in the Treatment of Restless Legs Syndrome- RIS- 1VIT3037-A Multi-center, Randomized, Double-Diinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer-ferric carbooymahiose in the Tenandomized, Double-Diinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer-ferric carbooymahiose injection- in Patients with Cancer- and Chemotherapy related Anemia 1VIT3035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Tertament Response of Intravenous Injectafer-Ferric Carbooymahiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1 1VIT3035-A Multi-center, Randomized, Open-label, Controlled study to Investigate the Tertament Response of Intravenous Injectafer-Ferric Carbooymahiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	GRUNKEMEER DORESWAMY DORESWAMY CHEDID WATSON	DAVID MEGHANA MEGHANA SOLLY PETER	PORTLAND SEATTLE SEATTLE BEETON KINSTON	WA	\$ 378 \$ 33,109 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA	Chemotherapy-related Anemia 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carbooymaltose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Inon deficient Anemia -1 1VIT14037 1VIT14037 A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer- For Carbooymaltose in the Treatment of Resides Legs Syndrome- 1SVIT14038 1VIT14038 1VIT140393 1VIT140393- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectaferferric carbooymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to investigate the Efficacy and Sort of Intravenous Injectafer Ferric Carbooymaltose- vs. Oral fron to Basien Petgolin Levels in Patients with Iron deficient Anemia -1 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to investigate the Treatment Response of Intravenous Injectafer Ferric Carbooymaltose- vs. Oral fron to Basien Petgolin Levels in Patients with Iron deficient Anemia -1 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer Ferric Carbooymaltose- vs. Oral fron to Basien Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035- AMILI-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer Ferric Carbooymaltose- vs. Oral fron to Basien Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035- AMILI-center, Randomized, Open-label, Controlled	GRUNKEMEER DORESWAMY DORESWAMY CHEDID WATSON STOCKWELL	DAVID MEGHANA MEGHANA SOLLY PETER DAVID	PORTLAND SEATTLE SEATTLE BELTON KINSTON VIRGINIA BEACH	WA	\$ 378 \$ 33,109 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLIC TIDEWATER INTEGRATED MEDICAL SERVICES, PLIC	Chemotherapy-related Anemia 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carbooymahizose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Into nedicient Anemia -1 3VIT14037 A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectuter- renric Carbooymantose- in the Treatment of Resides Legs Syndrome- 1VIT14037 1VIT14038 1VIT14039- 1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectaferferric carbooymantose injection- in Patients with Cancer- and Chemotherapy-related Anemia -1 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Efficacy and Series of Intravenous Injectafer Ferric Carbooymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer Ferric Carbooymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer Ferric Carbooymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035- AMILI-Center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer Ferric Carbooymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035- AMILI-Center, Randomized, Open-label, Controlled Response of Intravenous Injectafer- Ferric Londowymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 Very Controlled Study to Controlled Study to India to Valuate The Controlled Study to Controlled Study to India to Valuate Very	GRUNKEMEER DORESWAMY DORESWAMY CHEDID WATSON STOCKWELL STOCKWELL	DAVID MEGHANA MEGHANA SOLIY PETER DAVID	PORTLAND SEATTLE SEATTLE BELTON KINSTON VIRGINIA BEACH VIRGINIA BEACH	WA	\$ 378 \$ 33,199 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 5,733
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THOMAS CALLAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLLC	Chemotherapy-related Anemia 1VT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-Ferric Carbooymahizose-vs. Oral fron to Baseline Hepcidin Levels in Patients with fron deficient Anemia -1 1VT14037 1VT14037 A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carbooymahizose-in the Textament of Restless Legs Syndrome- INVT14037 1VT14038 1VT14039-A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectaferferric carbooymahizose injection- in Patients with Cancer- and Chemotherapy-related Anemia 1VT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Fficacy and Safety of Injectafer- InjectaferFerric Carbooymahizose- v. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carbooymahizose- vs. Oral fron to Baseline Hepcidin Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carbooymahizose- vs. Oral fron to Baseline Hepcidin Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carbooymahizose- vs. Oral fron to Baseline Hepcidin Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carbooymahizose- vs. Oral fron to Baseline Hepcidin Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carbooymahizose- vs. Oral fron to Baseline Hepcidin Study to Investigate the Treatment Response of Intravenous Injectafer- Ferric Carbooymahizose- vs. Oral fron to Baseline Hepcidin Study to Investigate the Study (Ferric to Quality of Life and Resource Utilization, of Injectafer- vs. Int	GRUNKEMEER DORESWAMY DORESWAMY CHEDID WATSON STOCKWELL	DAVID MEGHANA MEGHANA SOLLY PETER DAVID	PORTLAND SEATTLE SEATTLE BELTON KINSTON VIRGINIA BEACH	WA	\$ 378 \$ 33,109 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLIC TIDEWATER INTEGRATED MEDICAL SERVICES, PLIC	Chemotherapy-related Anemia 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carbooymatiose - vs. Oral fron to Baseline Hepcidin Levels in Patterts with fron deficient Anemia - I 1VIT12037 1VIT12037 1VIT12037 1VIT12037 1VIT12037 1VIT12039 1VIT12039 1VIT12039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- 1 carbooymatiose in the Treatment of Restless Legs Syndrome- 1815 1VIT12039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- 1 carbooymatiose injection: In Patients with Cancer- and Chemotherapy-related Anemia I 1 VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Teratement Response of Intravenous Injectafer Ferric Carbooymatiose - vs. Oral fron to Baseline Hepcidin Levels in Patients with fron deficient Anemia - I 1 VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer Ferric Carbooymatiose - vs. Oral fron to Baseline Hepcidin Levels in Patients with fron deficient Anemia - I 1 VIT13035-A Multi-center, Randomized, Open-label, Controlled 1 VIT13036-A Multi-center, Randomized, Open-label, Controlled 1 VIT13036-A Multi-center, Randomized, Open-label, Controlled 1 VIT13036-A Multi-center, Randomized, Open-label, Controlled	GRUNKEMEER DORESWAMY DORESWAMY CHEDID WATSON STOCKWELL STOCKWELL	DAVID MEGHANA MEGHANA SOLIY PETER DAVID	PORTLAND SEATTLE SEATTLE BELTON KINSTON VIRGINIA BEACH VIRGINIA BEACH	WA	\$ 378 \$ 33,199 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 5,733
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLIC TIDEWATER INTEGRATED MEDICAL SERVICES, PLIC TRI-COUNTY HEMATOLOGY AND ONCOLOGY, P.A.	Chemotherapy-related Anemial 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-ferric Carbooymatiose-vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13037- 1VIT13037- 1VIT13038-1VIT13039-1VIT113039-1VIT1113039-1VIT1113039-1VIT1113039-1VIT1113039-1VIT1111111-1VIT111111-1VIT11111111-1VIT1111111111	GRUNKEMEER DORESWAMY DORESWAMY OREOID WATSON STOCKWELL NAGAJOTH	DAVID MEGHANA MEGHANA SOLLY PETER DAVID NAGAPRASAD	PORTLAND SEATTLE SEATTLE BELTON KINSTON VIRGINIA BEACH VIRGINIA BEACH CANTON	WA	\$ 378 \$ 33,109 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 5,733
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLIC TIDEWATER INTEGRATED MEDICAL SERVICES, PLIC TRI-COUNTY HEMATOLOGY AND ONCOLOGY, P.A.	Chemotherapy-related Anemial 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-Ferric Carbooymanistose-vs. Oral fron to Baseline Hepcidin twelse in Patients with Into deficient Anemia -1 1VIT13037 - Double-Blind, Multi-Center, Randomized, Piscebo- 1VIT13037 - Double-Blind, Multi-Center, Randomized, Piscebo- 1VIT13037 - Double-Blind, Multi-Center, Randomized, Stedy of Injectsfer- 1VIT13038 - Description of Resides Legs Syndrome- 18.5 1VIT140393 - Multi-center, Randomized, Double-Blinded, Controlled 3VIT140393 - Multi-center, Randomized, Double-Blinded, Controlled 3VIVT14037 - Description of Resides Legs Syndrome- 1VIT13039 - A Multi-center, Randomized, Double-Blinded, Controlled 3vuly to Investigate the Efficacy and Safety of Injectaferferric carbooymantose injection- in Patients with Cancer- and Chemotherapy-related Anemia 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled 3vuly to Investigate the Treatment Response of Intravenous revels in Patients with Iron deficient Anemia -1 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous received in Patients with Iron deficient Anemia -1 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous received in Patients with Iron deficient Anemia -1 1VIT13035 - Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer Ferric Canboymanisose - Vor Olativo to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 VIT13035 - Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer Ferric Canboymanisose - Vor Olativo to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 VIT13035 - Multi-center, Randomized, Open-label, Controlled Study to Indexed - Vor Olativo to Base	GRUNKEMEER DORESWAMY DORESWAMY CHEDID WATSON STOCKWELL STOCKWELL	DAVID MEGHANA MEGHANA SOLIY PETER DAVID	PORTLAND SEATTLE SEATTLE BELTON KINSTON VIRGINIA BEACH VIRGINIA BEACH	WA	\$ 378 \$ 33,199 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 5,733
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLLC TIDEWATER INTEGRATED MEDICAL SERVICES, PLLC TRI-COUNTY HEMATOLOGY AND ONCOLOGY, P.A. TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC	Chemotherapy-related Anemia 1VT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-Ferric Carbooymanizose-vs. Oral fron to Baseline Hepcidin Levels in Patients with Inton deficient Anemia-1 1VT12037 1VT12037 A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carbooymanizose-in the Treatment of Restless Legs Syndrome- RUS- 1VT14037 1VT140339 1VT140339 1VT140339 1VT140339 1VT140393-A Multi-center, Randomized, Double-Blinded, Controlled Study to Investigate the Efficacy and Safety of Injectaferferric carbooymanizose injection- in Patients with Cancer- and Chemotherapy-related Anemia 1VT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Tirecay and Series of Intravenous InjectaferFerric Carbooymanizose- vo. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1 1VT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carbooymanizose- vo. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1 1VT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous InjectaferFerric Amemia-1 1VT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous InjectaferFerric, Carbooymanizose- vo. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1 1VT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous InjectaferFerric Carbooymanizose-vo. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1 1VT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-Ferric Carbooymanizose-vo. Oral fron	GRUNKEMEER DORESWAMY DORESWAMY OREOID WATSON STOCKWELL NAGAJOTH	DAVID MEGHANA MEGHANA SOLLY PETER DAVID NAGAPRASAD	PORTLAND SEATTLE SEATTLE BELTON KINSTON VIRGINIA BEACH VIRGINIA BEACH CANTON	WA	\$ 378 \$ 33,109 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 5,733
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLLC TIDEWATER INTEGRATED MEDICAL SERVICES, PLLC TRI-COUNTY HEMATOLOGY AND ONCOLOGY, P.A. TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC	Chemotherapy-related Anemia 1VT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-Ferric Carbooymanizose-vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1 3VT14037 1VT14037 A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carbooymanizose-in the Treatment of Restless Legs Syndrome- RUS- 1VT140339 1VT140339-A Multi-center, Randomized, Double-Blinded, Controlled Study to Investigate the Efficacy and Safety of Injectaferferric carbooymanizose in July 1 (1) (1) (1) (1) (1) (1) (1) (1) (1) (GRUNKEMEER DORESWAMY DORESWAMY OREOID WATSON STOCKWELL NAGAJOTH	DAVID MEGHANA MEGHANA SOLLY PETER DAVID NAGAPRASAD	PORTLAND SEATTLE SEATTLE BELTON KINSTON VIRGINIA BEACH VIRGINIA BEACH CANTON	WA	\$ 378 \$ 33,109 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 5,733
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLLC TIDEWATER INTEGRATED MEDICAL SERVICES, PLLC TRI-COUNTY HEMATOLOGY AND ONCOLOGY, P.A. TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC	Chemotherapy-related Anemial 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carbooymatiose - v. Oral fron to Baseline Hepcidic Levels in Patients with Into Relicitor Anemia - I 1VIT14037- A Double-Billind, Multi-Center, Randomized, Piscebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carbooymatose- in the Treatment of Restless Legs Syndrome- RIS- 1VIT14038- 1VIT14038- 1VIT14039- A Multi-center, Randomized, Double-Bilnded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- Carbooymatiose injection- in Patients with Cancer- and Chemotherapy-related Anemia - I 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Tentement Response of Intravenous Injectafer Ferric Carbooymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Tentement Response of Intravenous Injectafer Ferric Carbooymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Tentement Response of Intravenous Injectafer- Jerric Carbooymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Tentement Response of Intravenous Injectafer- Jerric Carbooymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Tertement Response of Intravenous Injectafer- Serric Carbooymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Terte	GRUNKEMEER DORESWAMY OORESWAMY OFFOID WATSON STOCKWELL STOCKWELL JONES	DAVID MEGHANA MEGHANA SOLLY PETER DAVID DAVID NAGAPRASAD MICHAEL	PORTLAND SEATTLE SEATTLE BELTON KINSTON VIRGINIA BEACH VIRGINIA BEACH CANTON CRESTVIEW HILLS	WA	\$ 378 \$ 33,109 \$ 7,562 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 5,733 \$ 1,800
THE OREGON CLINIC PC THE POLYCUNIC THE POLYCUNIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLIC TIDEWATER INTEGRATED MEDICAL SERVICES, PLIC TRI-COUNTY HEMATOLOGY AND ONCOLOGY, P.A. TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC TRI-STATE MOUNTAIN NEUROLOGY ASSOCIATES PC	Chemotherapy-related Anemial 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-ferric Carbooymatiose-vs. Oral fron to Baseline Hepcidin Levels in Patterts with fron deficient Anemia-1 1VIT13037- 1VIT13037- 1VIT13038- 1VIT14038- 1VIT14039- 1VIT14039- A Multi-center, Randomized, Double-blinde, Controlled Study to Investigate the Efficacy and Safety of Injectafer- 1erric Carbooymatiose-in the Treatment of Restless Legs Syndrome- 1815- 1VIT14039- 1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- 1erric carbooymatiose injection- in Patients with Cancer- and Chemotherapy-related Aniemial 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Teratement Response of Intravenous Injectafer-Ferric Carbooymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-Ferric Carbooymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-Ferric Carbooymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Tercenter Response of Intravenous 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Tercenter of Restless Legs Syndrome- 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Tercenter of Restless Legs Syndrome- 1VIT13035-A Multi-center, Randomized, Open-label, Controlled S	GRUNKEMEER DORESWAMY DORESWAMY CHEDID WATSON STOCKWELL STOCKWELL NAGAJOTHE JONES DENGLER	DAVID MECHANA MECHANA SOLLY PETER DAVID NAGAPRASAD MICHAEL JOHN	PORTLAND SEATTLE SEATTLE BELTON KINSTON VIRGINIA BEACH VIRGINIA BEACH CANTON CRESTVIEW HILLS JOHNSON CITY	WA	\$ 3788 \$ 33,109 \$ 7,5675 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 1,800 \$ 420 \$ 9,717
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLLC TIDEWATER INTEGRATED MEDICAL SERVICES, PLLC TRI-COUNTY HEMATOLOGY AND ONCOLOGY, P.A. TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC TRI-STATE MOUNTAIN NEUROLOGY ASSOCIATES PC	Chemotherapy-related Anemia 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-Aerric Carbooymahizes-vs. Oral fron to Baseline Hepcidin Levels in Patients with Intro deficient Anemia -1 1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectuter- renric Carbooymanizes- in the Treatment of Resides Legs Syndrome- 1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo- 1VIT14038- 1VIT14038- 1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectaferferric carbooymanizes injection- in Patients with Cancer- and Chemotherapy-related Anemia -1 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to investigate the Efficacy and Safety of Injectaferferric carbooymatose vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to investigate the Treatment Response of Intravenous injectafer Ferric Carbooymationse -V. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous injectafer Ferric Carbooymationse -V. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous injectafer Ferric Carbooymationse -V. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Reponse of Intravenous injectafer Ferric Carbooymationse -V. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035-A Multi-center, Randomized, Open-label, Con	GRUNKEMEIER DORESWAMY DORESWAMY CHEDID WATSON STOCKWELL NAGAJOTHI JONES DENGLER RITTER	DAVID MEGHANA MEGHANA SOLLY PETER DAVID NAGAPRASAD MICHAEL JOHN TIMOTHY	PORTLAND SEATTLE SEATTLE BELTON VIRGINIA BEACH VIRGINIA BEACH CANTON CRESTVIEW HILLS JOHNSON CITY SOUTHLAKE	WA TX NC VA OH KY TN	\$ 378 \$ 33,109 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 5,733 \$ 1,800 \$ 9,717
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLLC TIDEWATER INTEGRATED MEDICAL SERVICES, PLLC TRI-COUNTY HEMATOLOGY AND ONCOLOGY, P.A. TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC TRI-STATE MOUNTAIN NEUROLOGY ASSOCIATES, PSC TRI-STATE MOUNTAIN NEUROLOGY ASSOCIATES PC	Chemotherapy-related Anemia 1VT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carbonymanizose- vs. Oral fron to Baseline Hepcidin Levels in Patients with fron deficient Anemia -1 1VT14037- A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carbonymanizose- in the Tevatment of Restless Legs Syndrome- 1VT14037- A Double-Blind, Multi-Center, Randomized, Placebo- 1VT14038- 1VT14039- 1VT14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectaferferric carbonymatose injection- in Patients with Cancer- and Chemotherapy-related Anemia -1 1VT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Efficacy and Safety of Injectafer- Injectaferferric Carbonymiatose- v. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VT13035- A Multi-center, Randomized, Open-label, Controlled Souly to Investigate the Treatment Response of Intravenous Injectaferferric Carbonymiatose- v. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VT13035- A Multi-center, Randomized, Open-label, Controlled Souly to Investigate the Treatment Response of Intravenous Injectaferferric Carbonymiatose- vs. Oral for not Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VT13037- A Double-Blind, Multi-Center, Randomized, Open-label, Controlled Study to Investigate the Ferratment Response of Intravenous Injectaferferric Carbonymiatose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VT13037- A Double-Blind, Multi-Center, Randomized, Open-label, Controlled Study to Investigate the Ferratment Response of Intravenous Injectaferferric Carbonymiatose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VT13037- A Double-Bli	GRUNKEMEER GORESWAMY DORESWAMY CHEDID WATSON STOCKWELL STOCKWELL JONES DENGLER RITTER NIEDERMAN	DAVID MEGHANA MEGHANA SOLLY PETER DAVID NAGAPRASAD MICHAEL JOHN TIMOTHY THOMAS	PORTLAND SEATTLE SEATTLE BELTON VIRGINIA BEACH VIRGINIA BEACH CANTON CRESTVIEW HILLS JOHNSON CITY SOUTHLAKE BOYNTON BEACH	WA TX NC VA OH KY TN TX FL	\$ 378 \$ 33,109 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 1,800 \$ 9,717 \$ 378 \$ 2,908
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLLC TIDEWATER INTEGRATED MEDICAL SERVICES, PLLC TRI-STATE GASTROENTEROLOGY AND ONCOLOGY, P.A. TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC TRI-STATE MOUNTAIN NEUROLOGY ASSOCIATES PC TX DIGESTIVE DISEASE CONSULTANTS UNIVERSITY CANCER INSTITUTE LLC	Chemotherapy-related Anemia 1VT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carbooymahizose - vs. Oral fron to Baseline Hepcidin Levels in Patients with fron deficient Anemia - I 1VT14037 1VT14037 A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer - Ferric Carbooymantose in the Treatment of Restless Legs Syndrome- ILVT14037 1VT14037 1VT14038 1VT14039 1VT14039 - A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer - Ferric carbooymantose injection: In Patients with Cancer- and Chemotherapy-related Anemia 1VT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the German Carbooymantose - Voral fron to Baseline Hepcidin Levels in Patients with Intra Medicant Anemia - I 1VT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carbooymantose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Intra Medicant Anemia - I 1VT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carbooymantose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Intra Medicant Anemia - I 1VT1037- A Double-Blind, Multi-Center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carbooymantose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Intra Medicant Anemia - I 1VT11037- A Double-Blind, Multi-Center, Randomized, Open-label, Controlled Study to Investigate the Fersement Anemia - I 1VT11037- A Double-Blind, Multi-Center, Randomized, Open-label, Controlled Study to Investigate the Fersement Anemia - I 1VT11037- A Double-Blind, Multi-Center, Randomized, Open-label, Controlled Study to Investigate the Fersemen	GRUNKEMEIER DORESWAMY DORESWAMY CHEDID WATSON STOCKWELL NAGAJOTHI JONES DENGLER RITTER	DAVID MEGHANA MEGHANA SOLLY PETER DAVID NAGAPRASAD MICHAEL JOHN TIMOTHY	PORTLAND SEATTLE SEATTLE BELTON VIRGINIA BEACH VIRGINIA BEACH CANTON CRESTVIEW HILLS JOHNSON CITY SOUTHLAKE	WA TX NC VA OH KY TN	\$ 378 \$ 33,109 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 5,733 \$ 1,800 \$ 9,717
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLLC TIDEWATER INTEGRATED MEDICAL SERVICES, PLLC TRI-STATE GASTROENTEROLOGY AND ONCOLOGY, P.A. TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC TRI-STATE MOUNTAIN NEUROLOGY ASSOCIATES PC TX DIGESTIVE DISEASE CONSULTANTS UNIVERSITY CANCER INSTITUTE LLC	Chemotherapy-related Anemia 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-Ferric Carbooymaltose-vs. Oral fron to Baseline Hepcidin tweels in Patients with Intro delicited Anemia -1 1VIT14037 1VIT14038 1VIT14038 1VIT14038 1VIT14039 1VI	GRUNKEMEER GORESWAMY DORESWAMY CHEDID WATSON STOCKWELL STOCKWELL JONES DENGLER RITTER NIEDERMAN	DAVID MEGHANA MEGHANA SOLLY PETER DAVID NAGAPRASAD MICHAEL JOHN TIMOTHY THOMAS	PORTLAND SEATTLE SEATTLE BELTON VIRGINIA BEACH VIRGINIA BEACH CANTON CRESTVIEW HILLS JOHNSON CITY SOUTHLAKE BOYNTON BEACH	WA TX NC VA OH KY TN TX FL	\$ 378 \$ 33,109 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 1,800 \$ 9,717 \$ 378 \$ 2,908
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLLC TIDEWATER INTEGRATED MEDICAL SERVICES, PLLC TRI-COUNTY HEMATOLOGY AND ONCOLOGY, P.A. TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC TRI-STATE MOUNTAIN NEUROLOGY ASSOCIATES PC TX DIGESTIVE DISEASE CONSULTANTS UNIVERSITY CANCER INSTITUTE LLC UNIVERSITY OF KENTUCKY	Chemotherapy-related Anemia 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carbooymaltose- vs. Oral fron to Baseline Hepcidin tweels in Patients with Intro deficient Anemia -1 1VIT14037 1VIT14038 1VIT14038 1VIT14038 1VIT14038 1VIT14039	GRUNKEMEIER DORESWAMY DORESWAMY CHEDID WATSON STOCKWELL STOCKWELL NAGAJOTHE JONES DENGLER RITTER NIEDERMAN AL-SABBAGH	DAVID MECHANA MEGHANA SOLLY PETER DAVID NAGAPRASAD MICHAEL JOHN TIMOTHY THOMAS MOHANAD	PORTLAND SEATTLE BELTON SEATTLE BELTON VIRGINIA BEACH VIRGINIA BEACH CANTON CRESTVIEW HILLS JOHNSON CITY SOUTHLAKE BOYNTON BEACH LEXINGTON	WA WA TX NC VA OH KY TN TX FL KY	\$ 378 \$ 37,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 1,800 \$ 9,717 \$ 378 \$ 2,908 \$ 2,008
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLLC TIDEWATER INTEGRATED MEDICAL SERVICES, PLLC TRI-COUNTY HEMATOLOGY AND ONCOLOGY, P.A. TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC TRI-STATE MOUNTAIN NEUROLOGY ASSOCIATES PC TX DIGESTIVE DISEASE CONSULTANTS UNIVERSITY CANCER INSTITUTE LLC UNIVERSITY OF KENTUCKY	Chemotherapy-related Anemia 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carbooymatiose - vs. Oral fron to Baseline Hepcidin Levels in Patients with Into Relicitors Anemia - I 1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of injectafer- Ferric Carbooymatose- in the Treatment of Restless Legs Syndrome- RIS- 1VIT14038- 1VIT14038- 1VIT14039- A Multi-center, Randomized, Double-Blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- Carbooymatiose injection: In Patients with Cancer- and Chemotherapy-related Anemia 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Tentement Response of Intravenous Injectafer Ferric Carbooymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Into Reflicitor Anemia - I 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Tentement Response of Intravenous Injectafer Ferric Carbooymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Into Reflicitor Anemia - I 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Tentement Response of Intravenous Injectafer Ferric Carbooymatiose- vs. Oral fron to Baseline Hepcidin Level to Patients with Into Reflicitor Anemia - I 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Tentement Response of Intravenous Injectafer Ferric Carbooymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Into Reflicitor Anemia - I 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Tentement Response of Intravenous Injectafer Ferric Carbooymatiose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Into Reflicitor Anemia - I 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Ten	GRUNKEMEER GORESWAMY DORESWAMY CHEDID WATSON STOCKWELL STOCKWELL JONES DENGLER RITTER NIEDERMAN	DAVID MEGHANA MEGHANA SOLLY PETER DAVID NAGAPRASAD MICHAEL JOHN TIMOTHY THOMAS	PORTLAND SEATTLE SEATTLE BELTON VIRGINIA BEACH VIRGINIA BEACH CANTON CRESTVIEW HILLS JOHNSON CITY SOUTHLAKE BOYNTON BEACH	WA TX NC VA OH KY TN TX FL	\$ 378 \$ 33,109 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 1,800 \$ 9,717 \$ 378 \$ 2,908
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLIC TIDEWATER INTEGRATED MEDICAL SERVICES, PLIC TRI-COUNTY HEMATOLOGY AND ONCOLOGY, P.A. TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC TRI-STATE MOUNTAIN NEUROLOGY ASSOCIATES PC TX DIGESTIVE DISEASE CONSULTANTS UNIVERSITY CANCER INSTITUTE LIC UNIVERSITY OF KENTUCKY	Chemotherapy-related Anemia 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carbooymatiose - vs. Oral fron to Baseline Hepcidin Livers of the Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carbooymatiose - in the Treatment of Restless Legs Syndrome- 183. 1VIT14037 - Double-Billod, Multi-Center, Randomized, Piscebo- Ferric Carbooymatiose - in the Treatment of Restless Legs Syndrome- 183. 1VIT14038 - Investigate the Efficacy and Safety of Injectafer- Ferric Carbooymatiose - in the Treatment of Restless Legs Syndrome- 183. 1VIT14039 - A Multi-center, Randomized, Double-Billodd, Controlled Study to Investigate the Efficacy and Safety of Injectafer- Carbooymatiose injection - in Patients with Cancer- and Chemotherapy-related Aniemia 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer- Ferric Carbooymatiose - vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer- Ferric Carbooymatiose - vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carbooymatiose - vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Tertement Response of Intravenous Injectafer - Ferric Carbooymatiose - vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Tertement Response of Intravenous Injectafer - Ferric Carbooymatiose - vs. Oral fron to Baseline Hepcidin Leve	GRUNKEMEIER DORESWAMY DORESWAMY CHEDID WATSON STOCKWELL STOCKWELL NAGAJOTHE JONES DENGLER RITTER NIEDERMAN AL-SABBAGH	DAVID MECHANA MEGHANA SOLLY PETER DAVID NAGAPRASAD MICHAEL JOHN TIMOTHY THOMAS MOHANAD	PORTLAND SEATTLE BELTON SEATTLE BELTON VIRGINIA BEACH VIRGINIA BEACH CANTON CRESTVIEW HILLS JOHNSON CITY SOUTHLAKE BOYNTON BEACH LEXINGTON	WA WA TX NC VA OH KY TN TX FL KY	\$ 378 \$ 37,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 1,800 \$ 9,717 \$ 378 \$ 2,908 \$ 2,008
THE OREGON CLINIC PC THE POLYCUNIC THE POLYCUNIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THORAGIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLLC TIDEWATER INTEGRATED MEDICAL SERVICES, PLLC TIDEWATER INTEGRATED MEDICAL SERVICES, PLLC TRI-STATE GASTROENTEROLOGY AND ONCOLOGY, P.A. TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC. TRI-STATE MOUNTAIN NEUROLOGY ASSOCIATES PC TX DIGESTIVE DISEASE CONSULTANTS UNIVERSITY CANCER INSTITUTE LLC UNIVERSITY OF KENTUCKY UNIVERSITY OF KENTUCKY	Chemotherapy-related Anemia 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-ferric Carbonymatiose-vs. Oral fron to Baseline Hepcidin Levels in Patients with Intro deficient Anemia -1 1VIT13037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer-ferric Carbonymatiose-in the Treatment of Restless Legs Syndrome-BIS- 1VIT14037- Double-Blind, Multi-Center, Randomized, Dipuble-Blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer-ferric Carbonymatiose in Patients with Cancer-and Chemotherapy-related Anemia 1 1VIT14033- A Multi-center, Randomized, Double-Blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer-ferric carbonymatiose injection- in Patients with Cancer-and Chemotherapy-related Anemia 1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Teratment Response of Intravenous Injectafer-ferric Carbonymatiose-vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-ferric Carbonymatiose-vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-ferric Carbonymatiose-vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Efficacy and Safety of Injectafer-ferric Carbonymatiose-vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Tertement Response of Intravenous Injectafer-ferric Carbonymatiose-vs. Oral fron to Baseline Hepcidin Levels in	GRUNKEMEER DORESWAMY DORESWAMY CHEDID WATSON STOCKWELL STOCKWELL JONES DENGLER RITTER NIEDERMAN AL-SABRAGH	DAVID MIGHANA MEGHANA SOLLY PETER DAVID NAGAPRASAD MICHAEL JOHN TIMOTHY THOMAS MOHANAD	PORTLAND SEATTLE SEATTLE BELTON KINSTON VIRGINIA BEACH VIRGINIA BEACH CANTON CRESTVIEW HILLS JOHNSON CITY SOUTHLAKE BOYNTON BEACH LEXINGTON CHAPEL HILL	WA DX NC VA VA OH FY TN TX FE KY NC	\$ 378 \$ 33,109 \$ 7,5675 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 1,800 \$ 9,717 \$ 378 \$ 2,908 \$ 20,559 \$ 3,001
THE OREGON CLINIC PC THE POLYCUNIC THE POLYCUNIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THORAGIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLLC TIDEWATER INTEGRATED MEDICAL SERVICES, PLLC TIDEWATER INTEGRATED MEDICAL SERVICES, PLLC TRI-STATE GASTROENTEROLOGY AND ONCOLOGY, P.A. TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC. TRI-STATE MOUNTAIN NEUROLOGY ASSOCIATES PC TX DIGESTIVE DISEASE CONSULTANTS UNIVERSITY CANCER INSTITUTE LLC UNIVERSITY OF KENTUCKY UNIVERSITY OF KENTUCKY	Chemotherapy-related Anemia 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-ferric Carbonymatiose-vs. Oral fron to Baseline Hepcidin Levels in Patients with Intro deficient Anemia -1 1VIT13037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer-ferric Carbonymatiose-in the Treatment of Restless Legs Syndrome-BIS- 1VIT14037- Double-Blind, Multi-Center, Randomized, Dipuble-Blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer-ferric Carbonymatiose in Patients with Cancer-and Chemotherapy-related Anemia 1 1VIT14033- A Multi-center, Randomized, Double-Blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer-ferric carbonymatiose injection- in Patients with Cancer-and Chemotherapy-related Anemia 1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Teratment Response of Intravenous Injectafer-ferric Carbonymatiose-vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-ferric Carbonymatiose-vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-ferric Carbonymatiose-vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Efficacy and Safety of Injectafer-ferric Carbonymatiose-vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Tertement Response of Intravenous Injectafer-ferric Carbonymatiose-vs. Oral fron to Baseline Hepcidin Levels in	GRUNKEMEIER DORESWAMY DORESWAMY CHEDID WATSON STOCKWELL STOCKWELL NAGAJOTHE JONES DENGLER RITTER NIEDERMAN AL-SABBAGH	DAVID MECHANA MEGHANA SOLLY PETER DAVID NAGAPRASAD MICHAEL JOHN TIMOTHY THOMAS MOHANAD	PORTLAND SEATTLE BELTON SEATTLE BELTON VIRGINIA BEACH VIRGINIA BEACH CANTON CRESTVIEW HILLS JOHNSON CITY SOUTHLAKE BOYNTON BEACH LEXINGTON	WA WA TX NC VA OH KY TN TX FL KY	\$ 378 \$ 37,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 1,800 \$ 9,717 \$ 378 \$ 2,908 \$ 2,008
THE OREGON CLINIC PC THE POLYCUNIC THE POLYCUNIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLLC TIDEWATER INTEGRATED MEDICAL SERVICES, PLLC TRI-COUNTY HEMATOLOGY AND ONCOLOGY, P.A. TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC. TRI-STATE MOUNTAIN NEUROLOGY ASSOCIATES PC TX DIGESTIVE DISEASE CONSULTANTS UNIVERSITY CANCER INSTITUTE LLC UNIVERSITY OF KENTUCKY UNIVERSITY OF KENTUCKY	Chemotherapy-related Anemia 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-Ferric Carbooymanizose-vs. Oral fron to Baseline Hepcidin twels in Patients with fron deficient Anemia -1 1VIT14037-A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer- renric Carbooymanizose-in the Treatment of Residess Legs Syndrome- 1VIT14037-A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer- 1VIT14038-1 1VIT14039-1 1VIT14039-A Multi-center, Randomized, Double-Blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- 1VIT13039-A Multi-center, Randomized, Double-Blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Efficacy and Safety of Injectafer- 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer- Ferric Carbooymalose- v. Oral fron to Baseline Hepcidin Levels in Patients with Intro deficient Anemia -1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer- Ferric Carbooymalose- v. Oral fron to Baseline Hepcidin Levels in Patients with Intro deficient Anemia -1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer- Ferric Carbooymalose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Intro deficient Anemia -1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer- Ferric Carbooymalose-vs. Oral fron to Baseline Hepcidin Levels in Patients with Intro deficient Anemia -1 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to	GRUNKEMEER DORESWAMY DORESWAMY CHEDID WATSON STOCKWELL STOCKWELL JONES DENGLER RITTER NIEDERMAN AL-SABRAGH	DAVID MIGHANA MEGHANA SOLLY PETER DAVID NAGAPRASAD MICHAEL JOHN TIMOTHY THOMAS MOHANAD	PORTLAND SEATTLE SEATTLE BELTON KINSTON VIRGINIA BEACH VIRGINIA BEACH CANTON CRESTVIEW HILLS JOHNSON CITY SOUTHLAKE BOYNTON BEACH LEXINGTON CHAPEL HILL	WA DX NC VA VA OH FY TN TX FE KY NC	\$ 378 \$ 33,109 \$ 7,5675 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 1,800 \$ 9,717 \$ 378 \$ 2,908 \$ 20,559 \$ 3,001
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLLC TIDEWATER INTEGRATED MEDICAL SERVICES, PLLC TRI-COUNTY HEMATOLOGY AND ONCOLOGY, P.A. TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC TRI-STATE MOUNTAIN NEUROLOGY ASSOCIATES PC TX DIGESTIVE DISEASE CONSULTANTS UNIVERSITY OF KENTUCKY UNIVERSITY OF KENTUCKY UNIVERSITY OF NORTH CAROLINA UNIVERSITY OF NORTH CAROLINA UNIVERSITY OF NORTH CAROLINA HEALTH CARE SYSTEM.	Chemotherapy-related Anemia 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-Ferric Carbooymatiose- vs. Oral fron to Baseline Hepcidic Lord Carbooymatiose- vs. Oral fron to Baseline Hepcidic 1VIT14037- A Double-Billid, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carbooymatiose- in the Treatment of Restless Legs Syndrome- RIS- 1VIT14037- A Double-Billid, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carbooymatiose in the Treatment of Restless Legs Syndrome- RIS- 1VIT14038- 1VIT14039- A Multi-center, Randomized, Double-Bilnded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- 1VIT13039- A Multi-center, Randomized, Double-Bilnded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Teratement Response of Intravenous 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous 1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatm	GRUNKEMEER CORESWAMY DORSSWAMY CHEDID WATSON STOCKWELL STOCKWELL JONES DENGLER RITTER NIEDERMANN AL-SABBAGH SAACS	DAVID MIGHANA MEGHANA SOLLY PETER DAVID DAVID NAGAPRASAD MICHAEL JOHN TIMOTHY THOMAS MOHANAD	PORTLAND SEATTLE BESTON SEATTLE BESTON VIRGINIA BEACH VIRGINIA BEACH CANTON CRESTVIEW HILLS JOHNSON GITY SOUTHLAKE BOTHTON BEACH LEXINGTON CHAPEL HILL CHAPEL HILL	WA DX NC VA VA OH FY TN TX FE KY NC	\$ 378 \$ 33,109 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 1,800 \$ 9,717 \$ 378 \$ 2,908 \$ 2,001 \$ 1,901
THE OREGON CLINIC PC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLIC TIDEWATER INTEGRATED MEDICAL SERVICES, PLIC TRI-COUNTY HEMATOLOGY AND ONCOLOGY, P.A. TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC TRI-STATE MOUNTAIN NEUROLOGY ASSOCIATES PC TX DIGESTIVE DISEASE COMSULTANTS UNIVERSITY OF KENTUCKY UNIVERSITY OF KENTUCKY UNIVERSITY OF NORTH CAROLINA UNIVERSITY OF NORTH CAROLINA UNIVERSITY OF NORTH CAROLINA	Chemotherapy-related Anemia 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer-ferric Carbooymaltose-vs. Oral fron to Baseline Hepcidin twels in Patients with Into deficient Anemia -1 1VIT13037 - Double-Blind, Multi-Center, Randomized, Placebo- controlled Study to Investigate the Efficacy and Safety of Injectafer- ferric Carbooymaltose- in the Treatment of Restless Legs Syndrome- 8LS 1VIT14038 - Description of Restless Legs Syndrome- 8LS 1VIT140393 - Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the efficacy and Safety of Injectafer- ferric Carbooymaltose- in Patients with Cancer- and Chemotherapy-related Anemia -1 1VIT13035 - A Multi-center, Randomized, Opon-label, Controlled Study to Investigate the Tentament Response of Intravenous 1VICTAGE - Ferric Carbooymaltose- vo. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous 1VIT13035 - Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous 1VIT13035 - Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous 1VIT13035 - Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous 1VIT13035 - Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous 1VIT13035 - Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous 1VIT13035 - Multi-center, Randomized, Open-label, Controlled Study to In	GRUNKEMEER DORESWAMY DORESWAMY CHEDID WATSON STOCKWELL STOCKWELL JONES DENGLER RITTER NIEDERMAN AL-SABRAGH	DAVID MIGHANA MEGHANA SOLLY PETER DAVID NAGAPRASAD MICHAEL JOHN TIMOTHY THOMAS MOHANAD	PORTLAND SEATTLE SEATTLE BELTON KINSTON VIRGINIA BEACH VIRGINIA BEACH CANTON CRESTVIEW HILLS JOHNSON CITY SOUTHLAKE BOYNTON BEACH LEXINGTON CHAPEL HILL	WA DX NC VA VA OH FY TN TX FE KY NC	\$ 378 \$ 33,109 \$ 7,5675 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 1,800 \$ 9,717 \$ 378 \$ 2,908 \$ 20,559 \$ 3,001
THE OREGON CLINIC PC THE POLYCLINIC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLIC TIDEWATER INTEGRATED MEDICAL SERVICES, PLIC	Chemotherapy-related Anemia 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carbooymaltose- vs. Oral fron to Baseline Hepcidin tweels in Patients with Intro deficient Anemia -1 1VIT14037 1VIT14037 A Double-Blind, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer- Fire Carbooymaltose in the Treatment of Resides Legs Syndrome- 1SC, Carbooymaltose in the Treatment of Resides Legs Syndrome- 1SC, Carbooymaltose in the Treatment of Resides Legs Syndrome- 1SC, Carbooymaltose in the Treatment of Resides Legs Syndrome- 1SC, Carbooymaltose in the Treatment of Resides Legs Syndrome- 1SC, Carbooymaltose in State of Injectafer- 1VIT14038 1VIT14039: 1VIT14039: 1VIT14039: 1VIT14039 - A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Efficacy and Safety of Injectafer- 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer- 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer- 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer- 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer- 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Freatment Response of Intravenous Injectafer- 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Freatment Response of Intravenous Injectafer- 1VIT13035-A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Freatment Response of Intravenous Injectafer- 1VIT13035-A Multi-center, Randomi	GRUNKEMEIER DORESWAMY DORESWAMY CHEDID WATSON STOCKWELL STOCKWELL NAGAJOTHE JONES DENGLER RITTER RITDERMAN AL-SABBAGH ISAACS	DAVID MEGHANA MEGHANA SOLLY PETER DAVID NAGAPRASAD MICHAEL JOHN TIMOTHY THOMAS MCHANAD KIM KIM BROOKS	PORTLAND SEATTLE BELTON SEATTLE BELTON VIRGINIA BEACH VIRGINIA BEACH CANTON CRESTVIEW HILLS JOHNSON CITY SOUTHLAKE BOYNTON BEACH LEXINGTON CHAPEL HILL MOBILE	WA WA TX NC VA OH KY TN TX FE KY NC	\$ 378 \$ 378,57 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 16,500 \$ 2,000 \$ 2,000 \$ 378,500 \$ 2,005 \$ 2,005 \$ 2,000 \$ 3,001 \$ 19,901
THE OREGON CLINIC PC THE POLYCUNIC THE POLYCUNIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLIC TIDEWATER INTEGRATED MEDICAL SERVICES, PLIC TRI-COUNTY HEMATOLOGY AND ONCOLOGY, P.A. TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC TRI-STATE MOUNTAIN NEUROLOGY ASSOCIATES PC TX DIGESTIVE DISEASE CONSULTANTS UNIVERSITY OF KENTUCKY UNIVERSITY OF KENTUCKY UNIVERSITY OF NORTH CAROLINA	Chemotherapy-related Anemia 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carbooymaltose- vs. Oral fron to Baseline Hepcidin tweels in Patients with Intro Medicinet Anemia -1 1VIT14037 1VIT14038 1VIT14038 1VIT14038 1VIT14038 1VIT14039 1VIT14039 - A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- 1VIT14039 - A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- 1VIT14039 - A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Efficacy and Safety of Injectafer- 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer Ferric Carboymaltose vs. Oral fron to Baseline Hepcidin Levels in Patients with Into deficient Anemia -1 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer Ferric Carboymaltose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer Ferric Carboymaltose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer Ferric Carboymaltose- vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -1 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment R	GRUNKEMEIER DORESWAMY DORESWAMY CHEDID WATSON STOCKWELL STOCKWELL NAGAJOTHE JONES DENGLER RITTER RITDERMAN AL-SABBAGH ISAACS	DAVID MEGHANA MEGHANA SOLLY PETER DAVID NAGAPRASAD MICHAEL JOHN TIMOTHY THOMAS MCHANAD KIM KIM BROOKS	PORTLAND SEATTLE BELTON SEATTLE BELTON VIRGINIA BEACH VIRGINIA BEACH CANTON CRESTVIEW HILLS JOHNSON CITY SOUTHLAKE BOYNTON BEACH LEXINGTON CHAPEL HILL MOBILE	WA WA TX NC VA OH KY TN TX FE KY NC	\$ 378 \$ 378,57 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 16,500 \$ 2,000 \$ 2,000 \$ 378,500 \$ 2,005 \$ 2,005 \$ 2,000 \$ 3,001 \$ 19,901
THE OREGON CLINIC PC THE POLYCLINIC THE UNIVERSITY OF TEXAS MEDICAL BR. THOMAS ZIMMERMAN THOMAS ZIMMERMAN THORACIC & VASCULAR ASSOCIATES OF KINSTON PA TIDEWATER GASTROENTEROLOGY, PLIC TIDEWATER INTEGRATED MEDICAL SERVICES, PLIC TRI-COUNTY HEMATOLOGY AND ONCOLOGY, P.A. TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC TRI-STATE MOUNTAIN NEUROLOGY ASSOCIATES PC TX DIGESTIVE DISEASE COMSULTANTS UNIVERSITY OF KENTUCKY UNIVERSITY OF KENTUCKY UNIVERSITY OF NORTH CAROLINA UNIVERSITY OF NORTH CAROLINA UNIVERSITY OF NORTH CAROLINA	Chemotherapy-related Anemia 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carbooymatiose - vs. Oral fron to Baseline Hepcidin Livers of the Carbooymatiose - vs. Oral fron to Baseline Hepcidin 1VIT12037 - Double-Billod, Multi-Center, Randomized, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carbooymatiose - in the Treatment of Restless Legs Syndrome- 183. 1VIT14037 - Double-Billod, Multi-Center, Randomized, Double-Billod, Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carbooymatiose - In Patients with Cancer- and Chemotherapy-related Aniemia 1VIT13035 - A Multi-center, Randomized, Double-Billode, Controlled Study to Investigate the Efficacy and Safety of Injectafer- 1VIT13035 - A Multi-center, Randomized, Double-Billode, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer- Ferric Carbooymatiose - vs. Oral fron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer- Ferric Carbooymatiose - vs. Oral forto to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer- Ferric Carbooymatiose - vs. Oral forto to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer- Ferric Carbooymatiose - vs. Oral forto to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I 1VIT13035 - A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer- Ferric Carbooymatiose - vs. Oral forto to Baseline Hepcidin	GRUNKEMEIER DORESWAMY DORESWAMY CHEDID WATSON STOCKWELL STOCKWELL NAGAJOTHE JONES DENGLER RITTER RITDERMAN AL-SABBAGH ISAACS	DAVID MEGHANA MEGHANA SOLLY PETER DAVID NAGAPRASAD MICHAEL JOHN TIMOTHY THOMAS MCHANAD KIM KIM BROOKS	PORTLAND SEATTLE BELTON SEATTLE BELTON VIRGINIA BEACH VIRGINIA BEACH CANTON CRESTVIEW HILLS JOHNSON CITY SOUTHLAKE BOYNTON BEACH LEXINGTON CHAPEL HILL MOBILE	WA WA TX NC VA OH KY TN TX FE KY NC	\$ 378 \$ 378,57 \$ 7,567 \$ 2,000 \$ 9,012 \$ 7,000 \$ 16,500 \$ 16,500 \$ 2,000 \$ 2,000 \$ 378,500 \$ 2,005 \$ 2,005 \$ 2,000 \$ 3,001 \$ 19,901

Payee		Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total	
	1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled						
	Study to Investigate the Efficacy and Safety of Injectaferferric						
	carboxymaltose injection- in Patients with Cancer- and						
WAVERLY HEMATOLOGY ONCOLOGY PA	Chemotherapy-related Anemia	GRAHAM	Mark	CARY	NC	\$	17,830.00
	1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate					T	
	the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV						
	iron and Compare the Safety, Effect on Quality of Life and Resource						
Wellness Oncology and Hematology	Utilization, of Injectafer- vs. Int	SHAYE	OMID	WEST HILLS	CA	\$	378.00
	1VIT13035- A Multi-center, Randomized, Open-label, Controlled						
	Study to Investigate the Treatment Response of Intravenous						
	InjectaferFerric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin						
WEST HILLS GASTROENTEROLOGY ASSOCIATES PC	Levels in Patients with Iron deficient Anemia -I	GRUNKEMEIER	DAVID	PORTLAND	OR	\$	7,998.00
	1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled					T	
	Study to Investigate the Efficacy and Safety of Injectaferferric						
	carboxymaltose injection- in Patients with Cancer- and						
WESTCHASE CLINICAL ASSOCIATES INC	Chemotherapy-related Anemia	ARMAGHANY	TANNAZ	HOUSTON	TX	\$	567.00
WESTCHASE CLINICAL PLLC	1VIT14039	ARMAGHANY	TANNAZ	HOUSTON	TX	\$	7,500.00
WILLIAM ONDO	1VIT14037	·				\$	11,200.00